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HIGH-THROUGHPUT MAPPING OF THE BIOLOGICAL EFFECTS OF
PARTICLE THERAPY

Lawrence Fernando Bronk, M.S.
Advisory Professor: David Grosshans, M.D., Ph.D.
Radiation therapy is an essential tool in the cure of many cancer patients. Charged
particle based radiation therapies are gaining momentum as the physical dose distributions of
ions are superior to standard photons due their limited range. Additionally, charged particle
radiation has been shown to have linear energy transfer (LET) specific relative biological
effectiveness (RBE) when compared to photons. It is essential to employ accurate
biophysical models for particle beams in order to maximize the therapeutic potential of
particle therapy through the introduction of biologically optimized treatment planning. The
development of such models requires the support of large amounts of accurate physical and
biological data for each pristine beam. Unfortunately, such data are limited and difficult to
obtain.
This work presents the development of a high-throughput irradiation methodology
that utilizes automated high-throughput screening techniques to sample multiple locations
along a therapeutic ion therapy beam in a single irradiation. Using a special irradiation
apparatus designed and validated by our group, RBEs of adherent lung cancer cell lines at 12
positions along proton beams at the MD Anderson Proton Therapy Center (PTC) and the
Heidelberg Ion Therapy (HIT) facility were measured. RBEs for helium and carbon ion
vii

beams were also measured at the HIT facility. This system was further employed to perform
image-based, high-throughput mechanistic DNA damage response studies following
exposure to particles at varying LETs. Furthermore, the biological response to particles was
examined in additional model systems including glioma stem cell spheroids and normal rat
brain organoids.
For protons, all model systems demonstrated a rapid rise in RBE beyond the Bragg
peak. These findings contrast with several current model predictions which assume the RBE
trend linearly scales with proton LET. For the heavier particle measurements, we found
absolute RBE values and relative trends comparable to literature values. However, overkill
effects occurred for lower LETs than previously reported. DNA damage response assays
correlated with RBE measurements.
The discrepancy between model predictions and experimental data, especially in the
high-LET regions, requires rigorous experimental validation to ensure the accuracy of
existing models. The developed high-throughput irradiation system enables the rapid
measurement of biological response data which will contribute to a more complete mapping
of particle biological effects as well as biological susceptibilities of different cell types to
charged particle radiation. Ultimately, this knowledge will contribute to more comprehensive
biophysical models and the production of biologically optimized intensity-modulated particle
therapy plans.
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Introduction

Overview of radiation therapy and the current work
Radiotherapy is the targeted application of high-energy radiation to damage and kill
cancer cells while sparing surrounding healthy tissues. Approximately 60% of cancer patients
receive radiation in their treatment regime, often as the primary curative modality (1, 2).
Historically, external source radiation delivery was achieved using high energy gamma
photons produced from the radioactive decay of unstable elements. The most prevalent
radioisotope utilized was Cobalt-60 (T1/2 = 5.3 years) which produces photons with energies
of 1.17 MeV and 1.33 MeV for an average energy of 1.25 MeV. Co-60 is still presently used
in many areas around the world, especially in locations without consistent access to
electricity. The development of the linear accelerator (linac) in the 1920s eventually enabled
the generation of bremsstrahlung photons, also known as x-rays, with clinical application
beginning in the late 1950s (3). Later, the development of linear and circular particle
accelerators allowed for the acceleration of particles heavier than electrons to clinically
relevant energies.
While external beam radiotherapy is most often delivered with photons, or x-rays, in
recent years, there has been a growing interest towards utilizing charged particles to treat
patients. The motivation for using charged particle radiation as opposed to photons was
initially based on protons having a finite range allowing for improved dose distributions
covering the target tumor volume while reducing distal normal tissue damage (Figure 1).
However, it became evident that ions also exhibit unique biological effects compared to
photons with the biological response being directly related to the particle type as well as its
energy. Harnessing the differential biological effects of a given therapeutic ion beam by
1

placing the regions with minimum biological effect in normal tissues and those with
increased efficacy in the tumor volume are the main tenants driving biologically optimized
particle therapy.
Due to the purposed benefits associated with charged particle or ion therapy, it is
becoming an increasingly utilized radiation therapy modality. As the overall cost of particle
therapies continues to drop, it is predicted that the number of centers will increase
dramatically (4). While the most common form of charged particle therapy centers solely use
protons, there are 11 centers in the world already utilizing ions heavier than protons for
clinical treatments.
The clinical benefits of proton therapy, and to some degree particle therapy, remain
controversial due to the significantly increased costs and the as yet unconfirmed therapeutic
advantage compared to standard photon-based therapies for many disease presentations;
however, within the scientific literature, there is increasing evidence suggesting certain ions
present optimal peak to entrance dose biological effect as well as unique biological responses
to charged particle radiation including metastatic suppression and anti-tumor immune
activation (5-7).
In the current clinical practice of proton radiation therapy, the relative biological
effectiveness (RBE) of protons is a constant factor of 1.1 (8-10). This uniform RBE value
designates that to achieve an iso-effective response as compared to a photon-based treatment,
the dose delivered by protons must be reduced by 9.1%, an assumption derived from
experimental data mainly obtained at the middle of a spread-out Bragg peak (SOBP) region
from passive-scattering proton therapy (PSPT). Protons, being one of the lightest charged
particles frequently used in the clinic, are likely subject to a reduced signal to noise ratio
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when performing biological measurements due to the relatively small proportion of the beam
exhibiting high RBE, resulting in an unclear relationship between biological outcomes.
The standard proton beam delivery technique is now transitioning to a more advanced
beam scanning technology. This development allows for intensity-modulated proton therapy
(IMPT) by optimizing each constituent proton beamlet. While efforts have been made to
associate physical quantities with preclinical models to predict biologic effects of protons,
most of the existing models were developed based on data generated with PSPT and may not
be suitable to accurately predict the biological consequences for scanning beams due to the
differences in beam characteristics.
To facilitate the rapid measurement of accurate and precise proton beam biological
effects, our group has developed a methodology employing biological screening techniques
and a unique irradiation system (11). This method can readily be applied to additional
particle types used or under consideration for clinical use. Coupling these two highthroughput methods has enabled for efficient mapping of the biological effects of proton and
heavier charged particle radiation in several model systems spanning both cancer and normal
tissue.

3

Figure 1. Comparison of the application of protons and photons for radiation therapy. A
demonstrative treatment plan for a cranio-spinal irradiation (top) and focal radiation
therapy in the brain (bottom) from Dinh et al. published in Translational Cancer Research.
Treatment with protons results in improved dose distributions and reduces excess radiation
to off target volumes. Image from (12).

4

Physical mechanisms of action
The main requirement for external beam therapy is that the radiation must penetrate
through tissue to reach the deep-seated tumor volume. Charged particle and photon radiation
therapies ultimately achieve this effect but with different dose deposition profiles. X-rays are
the most common radiation used for cancer treatment. The metric used to denote the type of
photons delivered in the clinical setting is the accelerating potential experienced by the
electrons used to generate the x-rays. Accelerating voltage ranges are vendor and machinespecific, however, values between 4 and 18 MV are typical. The photon beam produced
within a linac utilizing the bremsstrahlung effect will contain a spectrum of photon energies
from a maximum energy of the accelerating potential to low energies. Low energy photons
are typically filtered out prior to leaving the linac. Upon entering a material, photons
primarily interact with the electrons present in an energy-dependent manner. These
interactions ionize local atoms by imparting energy to overcome electron binding energy thus
ejecting electrons from their initial location. The energized electrons will traverse the
material and deposit all the gained energy before finally coming to rest. In essence, a photon
beam can be viewed as creating a distributed electron field.
While photon interactions are stochastic in nature, protons constantly interact with the
medium they are traversing through with the energy deposition described by the Bethe
equation. As such, charged particles (electrons, protons, heavy ions, etc.) continuously lose
energy via electronic interactions as they traverse through a material. The rate of energy loss
increases as the particles lose energy. This phenomenon results in a dose deposition profile in
which the deposited energy is low at the entrance of a material and slowly increases with
depth. Towards the end of the particle range, the imparted energy rapidly increases and
5

abruptly drops to near zero when the particles stop via nuclear interactions. The highest point
of a charged particle dose deposition curve is known as the Bragg peak. In clinical practice,
most commonly, multiple beams are summed to apply a uniform dose over the tumor
volume. The summation of multiple particle beams to form a uniform dose volume is known
as a spread-out Bragg peak (SOBP) (Figure 3).
Physical parameters typically used to describe the particle energy transference over
the sensitive volume include the track- and dose-averaged linear energy transfer (LETt and
LETd), with LETd more frequently cited (Figure 4). Listing the depth of the measurement as
a quantifying metric for comparison is also common due to inherent limitations and
complications Monte Carlo (MC) code packages experience with low energy physics
interactions. A further confounding factor is that the particles within a clinically relevant
volume can exhibit a large energy distribution making the determination of LET effects
difficult.
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Figure 2. Basic comparison of the dose deposition of a clinical proton and photon beam.
Upon entering a material, photon beams have an initial increase in the dose deposition as
the photons interact with the material’s electrons and the ejected electron buildup reaches
electronic equilibrium. After this point, photons deposit dose in a stochastic manner
following an exponential decay relationship. Protons, being charged particles, have a finite
range within a material. This range is dependent on the initial particle energy. For a deepseated tumor, the radiation beam must penetrate the patient to reach the volume resulting in
dose deposited in healthy tissue. The photon beam will continue beyond the tumor volume,
depositing dose to distal tissues whereas the proton beam is made to stop after the cancerous
volume. Published by the Australian National Proton Facility Steering Committee in 2001.
Accessed from (13).
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Figure 3. The formation of an SOBP. The current practice in proton therapy is to treat the
tumor volume with a uniform physical dose and uniformly apply the biological correction
factor of 1.1 to the total irradiated volume. A spread-out Bragg peak is created by the
superposition of multiple beam energies. Historically this spread was achieved by passing
the beam through a multi-tiered spinning modulation wheel that would effectively present
different material thicknesses to the beam entering the treatment room from the beam line.
Newer spot scanning technology changes the beam energy at the synchrotron to achieve a
similar effect.
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Figure 4. LET present within an SOBP. The LET present within the entrance plateau of a
clinical proton beam is initially low. The SOBP is created by the addition of protons with
numerous energies. As the protons within a given beamlet begin to slow down and stop their
LET increases. The first LET increase is due to the lowest energy protons stopping within the
SOBP. The LET then increases with depth as a relatively larger portion of the total beam
begins to stop. The distal portion of the SOBP is derived from a single initial beam energy
(Figure 3). The superposition of numerous beamlets within an SOBP serves to broaden the
energy spectrum in any region of the SOBP. Many radiobiological experiments in the
literature have been performed mid-SOBP.

9

Treating cancer with radiotherapy
The understanding of cancer as a disease and how best to treat the condition is a
constantly evolving landscape. The current understanding of cancer is that it is not a single
disease, but rather a blanket term for a condition where normal cell processes have become
dysfunctional. In opposition to normally functioning tissues, the preeminent hallmarks of
cancer were defined in 2000 by Weinberg and Hanahan in a seminal work as: sustaining
proliferative signaling, evading growth suppressors, resisting cell death, replicative
immortality, sustaining angiogenesis, and metastatic potential (14). In a 2010 update, the
additional traits of avoiding immune destruction, promoting genomic instability and
subsequent mutation, abnormal metabolism, and inflammation were added (15).
The primary aim of radiation therapy is to deliver a sufficient dose to halt and reverse
tumor progression. At the cellular level, the effect of tumor response is usually referred to as
causing cell death. In this context, “death” is an ambiguous term. The delivery of ionizing
radiation serves to reduce tumor burden through available mechanisms of physical cell death
such as apoptosis or reproductive death such as mitotic catastrophe resulting in cellular
senescence. The tumor control probability is sigmoidal in nature indicating a limited number
of clonogenically viable cells present within a tumor, and thus tumor control results at a
threshold damage level which effectively reduces the number of these cells to zero. Cancer
cell death and thus tumor control increases with radiation dose; however, the delivery of a
radiation dose to achieve the desired clinical outcome is ultimately limited by pathological
tolerances of the normal tissues adjacent to the tumor. The normal tissue complication
function also presents as a sigmoidal response above which complications are expected to
rise rapidly (3). The normal response and tolerance to radiation exposure is tissue specific.
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As the biological control processes, i.e. tumor suppressive effects, in normal tissue cells are
by definition functional, radiation damage will either be repaired or the irreparably damaged
cell will undergo apoptosis.

Biologically optimized treatment planning
In the current clinical practice of proton therapy, techniques such as PSPT are
routinely used. In PSPT, a pristine proton beam is scattered laterally and modulated
longitudinally to create the SOBP (16). This volume is shaped by introducing materials into
the beam to conform it to the three-dimensional shape of the clinical treatment volume
(CTV). The largest contributing proton beam within a PSPT delivery is from the beam
required to reach the distal end of the CTV. As such, most of the dose to the formation of the
distal edges of beams are produced from a single beam energy.
IMPT is a newer modality where the dose is delivered to the target volume by
magnetically scanned small pristine proton beams. In contrast to PSPT, scanning beam
delivery increases the conformality of high dose regions to the target volumes. IMPT is an
evolving technology and there is ambiguity in the field as to what it comprises (17, 18). One
definition of IMPT is the application of scanning beams in any manner. However, recent
trends indicate IMPT should be categorized into single field optimized (SFO) or multi-field
optimized (MFO) IMPT. In SFO-IMPT, inverse planning is employed to optimize beamlet
intensities of each beam to independently conform to the entire target volume. In MFOIMPT, there is simultaneous optimization of all beamlets of all beams to deliver a
homogeneous prescription dose to the target while limiting the dose to critical volumes of
normal tissues to within tolerance levels. For complex target shapes and anatomic
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geometries, MFO-IMPT most effectively allows for optimal balancing of tumor coverage and
normal tissue sparing (19-21).
With both PSPT and SFO-IMPT the treatment is optimized to create a uniform dose
in the target volume without consideration of the varying biological effectiveness of the
particles in the beam. Thus, the distal high LET regions of PSPT and SFO beams are nearly
always in normal tissues distal to the target volume. With current MFO-IMPT techniques, the
location of high LET regions is uncontrollable. To reduce the probability of normal tissue
injury, current practitioners attempt to avoid placing such biologically active regions in
sensitive normal tissues, sometimes at the cost of compromising tumor dose or even raising
normal tissue doses (22).
With MFO-IMPT’s ability to control each individual beamlet intensity, there is no
impediment to selectively placing high LET and/or RBE regions within the tumor volume
while avoiding normal tissues. This delivery strategy would effectively allow for improved
normal tissue sparing and dose escalation to targets while ensuring treatments meet the
standard of care. Two obstacles exist for this implementation. First, the appropriate biologic
effect models for use in treatment planning are unknown, specifically for normal tissues.
Secondly, the optimization of IMPT involves adjustment of intensities (weights) of thousands
of beamlets comprising multiple beams aimed at the target from different directions.
Typically, the optimization process iteratively minimizes the objective function composed of
multiple competing sub-objectives. For biological effect (or LET)-based optimization, LET
distributions must be computed. Conventional semi-empirical methods of dose calculation
are not sufficiently accurate, whereas the most accurate methods, i.e., Monte Carlo
techniques are relatively slow.
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Biological models and endpoints

Clonogenic survival
A ubiquitous trait of cancer is the ability of the cells to sustain continual clonal
reproduction given ideal circumstances. In the laboratory setting this characteristic translates
to a single viable biologically immortal cell such as cancer or bacteria sufficiently replicating
to form a cluster of cells. These clusters of cells are referred to as colonies, as the method of
reproduction is asexual. The most common assay in the field of radiation biology is the
clonogenic assay which is designed to test the ability of a treatment to affect the
clonogenicity, the ability to form colonies, of cells. In this assay, single cells are exposed to a
variable of interest and allowed to grow for a time period to form colonies (23). Following an
insult such as radiation exposure, cells will attempt to repair damage sustained if possible.
Following this repair period, the fate of the cell is determined. Possible cell fates include
apoptosis, autophagy, senescence, quiescence, necrosis, necroptosis, etc., however, the
clonogenic assay combines all cell fates to measure a single metric, the reproductively viable
survival. Clonogenically viable cells will replicate and form colonies while irreparably
damaged cells will be unable to form a colony of at least 50 cells. A colony is generally
defined as a cluster of 50 or more cells (24). While damaged cells may still attempt to
continue through the cell cycle, with some replicating, the probability of a nonclonogenically viable cell to undergo 5-6 population doublings to successfully form a colony
of at least 50 cells is low.
There are complicating factors that must be considered when utilizing the clonogenic
assay. An intrinsic limitation within the clonogenic assay is cell counting accuracy. Even at
the theoretical limit, the associated counting and seeding error for a standard cell solution is
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approximately 15%-30% (25, 26). This error results in inherent noise to clonogenic data and
introduces compounding uncertainty when the number of cells per dose are counted
separately.
All cell lines have inherent biological sensitivities to culturing conditions that may or
may not affect the outcome of a clonogenic experiment. The impact of stress induced by
plating on the clonogenicity cells can be minimized by plating the cells prior to irradiation
and allowing them to reattach and recover (27). However, the effects of cell synchronization
can result in systematic changes in the observed radiosensitivity (28).
Conversely, seeding cells following radiation exposure adds factors that contribute to
the biological endpoint, resulting in increased uncertainty. Immediate post-irradiation plating
involves the effects of cell detachment during seeding while the cells are still repairing
radiation-induced damage (29). In particular, detaching cells and placing them into
suspension alters the cellular and thus nuclear shape from cylindrical to spherical. This
morphological change has been shown to result in a change of radiosensitivity due to the
increased number of neighboring chromosomes available for exchange (30, 31). In addition
to anchorage-dependent signaling and morphologic changes adherent cells undergo during
detachment, enzymatic detachment solutions, such as trypsin, cleave membrane-bound
adhesion molecules that function as major signalers in cellular stress responses, including
apoptosis (30, 32-34). Post-irradiation cell detachment can further confound determination of
RBE because photons and ions have different effects on cell adhesion and motility (35-38).
As such, immediate post-irradiation plating readouts involve coupling the effect of the
radiation treatment with cellular reattachment, except in the plating efficiency control used to
determine overall surviving fraction (SF) levels. Another complicating factor of post-
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irradiation plating is the possible contribution of repair of potentially lethal damage to cell
survival depending on the experimental conditions and timeline (24, 39-41).
Additional effects reported in the literature affecting the clonogenic assay readout are
multiplicity, clump effects, seeding density effects, and the bystander effect. The clonogenic
assay assumes that a colony is formed from a single cell. This is achieved by preparing and
seeding a single-cell suspension as well as preventing the forming colonies from clumping.
Multiplicity refers to the effect present when a colony forming unit (CFU) is derived from
multiple cells and can occur when the seeding solution does not solely consist of single cells,
but also contains doublets, triplets, etc. (42, 43). Seeding multiple cells per CFU serves to
artificially increase the measured radioresistance of a cell line as multiple lethal hits are
required to inactivate a CFU derived from more than a single cell. Low values of multiplicity
exhibit small effects on the overall SFs, and can be corrected by determining the multiplicity
of the seeding solution at the time of irradiation. The effects of clumps in a clonogenic
seeding solution result in a similar effect as high multiplicity (44).
Seeding density effects occur when the plating efficiency of a given cell line is
dependent on the number of cells placed within an assay well (45). This artifact is
particularly troublesome because it typically affects plates seeded at a lower cell density such
as the plating efficiency standard and thus impacts the overall normalization of the SF
results. In order to minimize this effect, plating efficiency can be measured over a range of
concentrations to ensure linearity prior to experimentation.
The bystander effect is reported in the literature as the effect cellular damage and
subsequent loss of clonality or death have on surrounding cells (46). It has been reported that
culturing unirradiated cells with cells exposed to radiation reduces the clonogenicity of the
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unirradiated cells. The exact extent this role plays in effecting the outcome of clonogenic
experiments is unclear.
The colony readout also determines the accuracy and reproducibility of the
clonogenic assay. With an increasing amount of damage and thus cell death, additional
changes are observed in cellular morphology. In particular, cells become smaller or larger
and the presence of giant cells is frequently reported (47-49). This cellular morphology can
be mistaken for viable colonies when scoring by the unaided eye or automated techniques.
Ideally, the conversion of raw clonogenic data to the corresponding SF via
normalization to the controls followed by further normalization when comparing RBEs has
the effect of minimizing the contribution of extraneous biological effects with the assumption
that they are present with all conditions and colony scoring is reproducibly performed. The
complicating factors associated with the clonogenic assay are well described as it has been
used first in the field of microbiology and then in mammalian cell lines to assess cellular
reproductive integrity after an insult for more than 60 years (47). As such, the understanding
of this simple assay has produced a rich amount of relevant literature to draw upon. Although
applying the results of in vitro assays to in vivo models has its own complications and is
frequently met with skepticism, clonogenic survival is by far the most well correlated cellular
based assay for tumor control probability, with substantial evidence establishing the relation
between the two methods (50-53).

The linear-quadratic model
There are many effect models used to fit the results of the clonogenic assay. These
models include but are not limited to the linear-quadratic (LQ), linear-quadratic-linear
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(LQL), lethal potentially lethal (LPL), microdosimetric-kinetic-model (MKM), repairmisrepair-fixation (RMF), and local effect model (LEM). The simplest and most common
model used is the LQ model. In the LQ model, the ability of radiation to induce a lethal DNA
lesion is given as:
𝐿 ∝ 𝛼𝐷 + 𝛽𝐷'
Where D is the dose delivered, and a and b are fitting parameters representing the amount of
directly lethal and potentially lethal lesions. With the assumption that lethal lesions are
Poisson distributed within a population of cells, the surviving fraction is then:
𝑆𝐹 = 𝑒 ,- = 𝑒 ,(/0120

3)

The LQ model has been shown to be an accurate model over a large range of doses
from sparsely-ionizing radiation, such as those delivered by photons; however, based on
microdosimetric considerations of the radiation track structure, deviations from the
assumption that lethal lesions are Poisson distributed within a population of cells are
expected for densely ionizing radiations such as heavy ions (54). For protons, being light
ions, the expected deviations from the LQ-model are ambiguous.

Relative biological effectiveness
RBE is defined as the ratio of doses between two types of radiation to produce an
equal biological response:
𝑅𝐵𝐸 =

𝐷𝑜𝑠𝑒:;<=>;?
(𝑎𝑡 𝑖𝑠𝑜𝑒𝑓𝑓𝑒𝑐𝑡)
𝐷𝑜𝑠𝑒@AB=

The type of control radiation is usually photons generated from Co-60 or 250 kVp xrays; however, practically, no de facto control radiation is currently established (5, 9). Other
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photon sources typically found in preclinical biological irradiators and thus frequently cited
as photon control radiations are the gamma rays produced from Cs-137, and 125 and 320
kVp x-rays. Clinically utilized photon sources are also found as control radiations with 6 MV
x-rays being the most common. The selection of a control radiation is critical as the literature
suggests differential responses between these sources with lower energy sources typically
resulting in higher RBEs than higher energy sources (55-57).
Quantifying and understanding differential biological responses is an active area of
research within radiobiology. Current proton therapy clinical practice attributes a spatially
uniform RBE value of 1.1 while this value continues to be debated, for ions heavier than
protons, the clinically used RBEs are spatially variant and on the order of 2-4 (58).
In a recent review, Paganetti systematically obtained and analyzed hundreds of
published clonogenic data points to characterize proton RBE (9). This review stated that
although the use of an RBE of 1.1 is acceptable when using large clinical SOBPs, the
literature does support increased RBE values of 1.15 mid-SOBP, 1.35 at the distal edge of the
SOBP, and 1.7 in the distal falloff of a SOBP. The review stresses the large spread of the
existing clonogenic data in the literature and emphasizes the unmet need for experimental
protocol standardization. In particular, Paganetti found that when attempting to fit the
compiled clonogenic dataset to a linear model to determine data trends, the results of the
analysis were heavily dependent on whether the associated clonogenic data errors were taken
into account. In many cases, the trends changed when the reported errors were accounted for.
However, the range of reported errors was also found to vary to a degree that was deemed to
be unrealistic. Paganetti called for comprehensive results reporting of model fit parameters
and errors.
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DNA damage repair and complexity
It is generally accepted that the most prominent biological effector of radiation
damage is the DNA contained within the cell nucleus (59). The DNA damage response
(DDR) is a complex process involving numerous proteins and effectors. The main types of
DNA damage induced by radiation exposure are base damage, single-strand breaks, and
double-strand breaks (DSB). DSBs are the most difficult DNA lesion to repair and are thus
considered the most lethal form of DNA damage. The two major DSB repair pathways are
non-homologous end joining (NHEJ) and homologous recombination (HR) (60).
Homologous recombination is an error free method of DSB repair that requires an
undamaged DNA template found in a sister chromatid. NHEJ is an error-prone process where
the hanging ends of a DSB are ligated to one another. For normal mammalian cells, the only
time duplicate DNA strands are present and HR can occur is during late S phase and the
following gap phase, G2, prior to the completion of mitosis. Conversely, the NHEJ pathway
may be utilized at all times of the cell cycle. Even when a duplicate DNA template is
available, cells will not always utilize the HR pathway for repair. The comprehensive
mechanism determining DNA repair pathway selection is still being elucidated, but it is clear
that is it a multifaceted process (61-63).
Markers of DNA damage assessment include the repair proteins which accumulate at
the site of a DSB. When imaged these proteins appear as small foci when the DNA damage is
localized within a small region of the nucleus subsequently recruiting repair proteins (Figure
5). DNA damage repair kinetics following irradiation can be measured by fixing cells at
different time points post-exposure, labeling the repair proteins, and scoring the number of
foci present. There are many repair proteins involved in DNA repair, and thus potential
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markers for measuring the DDR kinetics. Studying the total induction and repair of DSB foci
requires foci markers that are recruited to the site of DNA damage for all induced DSBs, and
are thus upstream of the repair pathway selection process. Two well established ubiquitous
DSB markers are gH2AX and p53 binding protein 1 (53bp1) (64, 65) In response to DSBs,
ser139 on the histone H2AX becomes phosphorylated by members of the PI3K family
forming gH2AX. This modification is thought to aid in the recruitment of repair proteins to
the site of damage. 53bp1 binds to damaged chromatin following histone modification and
plays a crucial role in the regulation of repair pathway selection (61).
Persistent DNA damage, particularly DSBs, has been described as a mechanistic
marker directly related to cellular survival. It also serves as a predictive marker of genomic
instability (66-69). It is thought that the complexity of the induced DNA lesion is directly
related to the probability of successful repair. There is significant evidence suggesting that
exposure to radiation with increasing LETs yields complex DSBs resulting in increased
biological effectiveness (64, 70-73).
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Figure 5. Representative DSB foci image. A common method to measure DSB repair kinetics
is to label the proteins involved in the DNA repair. Two established ubiquitous DSB markers
in the literature are gH2AX and 53bp1.
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3-dimensional tissue culture and organoids
In recent years there has been an active effort within the biomedical research
community to transition to advanced in vitro models that more closely recapitulate in vivo
settings than 2-dimensional in vitro experiments (74, 75). The motivation for this shift is to
increase the translation success rate from basic in vitro studies to improved clinical outcomes
(76, 77).
The crucial roles that both the tumor microenvironment and host immune system play
in the response to therapeutic treatment has entered the forefront of the cancer research field
(78-82). In simplified adherent monolayer models, interactions between the myriad of cell
types present within in vivo settings are not present. Additionally, even within the same cell
line, gene and protein expression levels vary when cultured in two or three dimensions (75,
83). Mounting evidence has demonstrated that three-dimensional organoid models are more
representative of in vivo settings than classic cellular monolayers.

Modeling the relationship of dose, LET, and RBE
Dose and LETd are the two key physical parameters commonly used in reporting the
RBE of protons which have been used as input parameters in several radiation response
models (84-86). Currently, there exist two major viewpoints for the relationship between
RBE and LETd: linear and non-linear. The McNamara model is a recently devised
phenomenological model based on all published in vitro datasets at the time of its
development (2015). This model predicts a linear relationship between proton RBE and LETd
(84). Other earlier developed phenomenological models also support a linear relationship
(85-88). However, the latest version of the LEM currently used for carbon ion therapy (LEM
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IV), perhaps the most developed and mechanistically sound model, predicts a non-linear
behavior of RBE with LETd (89).
Not all biological response models use LET as a parameter. For example, the RMF
model is a mechanism-based model that accounts for DNA damage induction and repair (90).
Polster et al. compared RBE values along an SOBP created by PSPT beams calculated using
eight different models (90-93). Their calculations show that the RBE values from all tested
models have obvious differences from each other and from experimental data (94). The
discrepancy between model predictions and experimental data is one of the main motivations
for the presented work with the goal to increase experimental verification of the accuracy of
existing models.
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Methods
Monte Carlo Simulations
Monte Carlo simulations using the latest releases of the Geant4 simulation software
package were used to calculate the doses and LETs associated with particle beams (95, 96).
The results of a MC simulation are directly dependent on how well the simulation setup
parallels the physical experimental the setup (Figure 6). This includes the corresponding
physical parameters of the materials utilized. The results of MC simulations presented in this
work are from collaboration with medical physicists. Dr. Fada Guan performed all MC
simulations for proton irradiations preformed at MDA. All MC calculation results presented
for irradiations performed at HIT were calculated by Dr. Darshana Patel.

2D Cell Culture

Cryogenic retrieval and cell line stock creation
Cell lines stocks arrive as frozen 1mL-2 mL aliquots in culture media or FBS with
5% dimethyl sulfoxide (DMSO). Upon arrival, the cells were rapidly thawed in a 37°C water
bath and 1:10 diluted in warm culture media within a standard 15 or 50 mL conical tube. The
cells were then pelleted via centrifugation at 1200 rpm for 5 minutes and the liquid solution
was aspirated to remove DMSO from the solution. The cell pellet is then resuspended in
culture media, plated into tissue-culture treated plasticware, and incubated at 37°C and 5%
CO2 for expansion. When culture confluence reaches approximately 70-90%, cells are
collected and 1.5 mL aliquots are dispensed in cryo-vials at a concentration of 2E6 cells per
vial using a freezing media consisting of 10% DMSO in FBS. The stocks are then placed
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within a freezing container to achieve a freezing rate of -1°C/min and placed in a -80°C
freezer overnight. The aliquots are then transferred to a liquid nitrogen cryostat for long-term
storage.

Cell lines and media
Two non-small cell lung cancer (NSCLC) cell lines, NCI-H460 (HTB-177) and NCIH1437 (CRL-5872), were obtained from American Type Culture Collection (ATCC). The
culture media utilized with these cell lines was RPMI 1640 supplemented with 10% fetal
bovine serum (FBS) and 1% penicillin-streptomycin.
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Figure 6. Overview of Monte Carlo simulation setup vs reality. The accuracy of Monte Carlo
simulations is directly dependent on how representative the simulation is of the actual setup
as well as to what accuracy the material physical properties are known (e.g. density,
interaction cross sections, ionization potential, etc.).
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Culturing and passaging
Cell lines are cultured in a humidified incubator at 37°C and 5% CO2. Subculturing is
typically performed when cell confluency reached 70% to 90%. The cells are collected using
a detachment solution such as a digestion or protease agent that cleaves cellular membrane
proteins. In particular, culture media is aspirated from the edge of the tissue culture flask. A
quick wash is performed using warm 0.25% trypsin-EDTA (trypsin). The wash solution is
aspirated, and replaced with fresh 0.25% trypsin for cellular detachment. The amount of
trypsin used was 1 mL per 25cm2 of culture vessel surface area. The culture container is then
placed in a humidified incubator for detachment to occur. For a fresh 0.25% trypsin solution
this period was approximately 2-3 minutes. Time for detachment increases for older solutions
and lower trypsin concentrations. Complete detachment is confirmed using an inverted light
microscope at a low magnification (4-10x) and examining the edges of the culture vessel. If
necessary, additional mechanical cellular detachment was utilized by gently tapping along
the periphery of a flask. Following cell detachment, the digestion agent is neutralized by
adding culture media at a volume at least 4x the volume of the trypsin. For example, 3 mL of
trypsin used for cellular detachment in a T-75 flask is diluted to a total of 15 mL by the
addition 12 mL of culture media. The cellular solution is then diluted into a new culture
vessel with culture media and returned to the incubator for attachment and growth. Typically
dilution factors are 1:5-1:10.

Determining cell concentration
Cells are detached and initially diluted to create a single cell suspension as in the
section above. The concentration and viability of cells within the solution is determined by
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dye exclusion. A sample of the stock cell solution is diluted with an equal volume of 0.04%
trypan blue. Viable cells will prevent the dye from entering the cell while the dye will stain
non-viable cells by penetrating the membrane. The dye-cell solution is then dispensed into
the appropriate container for the respective counting method to be used. Manual counting
was performed using a hemocytometer. An EVE Automated Cell Counter was used for lowthroughput automated counting, and a Vi-Cell XR system was used for high-throughput
automated counting. For both the hemocytometer and low-throughput automated counting
the cell solution is dispensed within a small rectangular chamber slide via capillary action.
The slide is then inserted into an automated cell counting system utilizing image based
scoring to score viable and dead cells.

Traditional clonogenic assay
Exponentially growing cells (approximate confluency 70-90%) were detached and the
cell concentration of the single cell suspension was determined as previously described. The
stock solution was diluted to form a single dispensing solution with a concentration of 1 cell
per µL. For the standard 6-well clonogenic assay, cells were seeded at concentrations ranging
from 100-3000 cells per well in a total volume of 3 mL per well. To promote even cell spatial
distributions within each well of the 6-well plate, the time following cell plating and
placement within an incubator was minimized. Cells were allowed to attach and stabilize in
culture for 8-10 hours before irradiation. The 6-well plates were brought into the treatment
room one at a time for irradiation and immediately returned to culture following radiation
exposure. Control plates were sham irradiated. Following irradiation, cells were cultured for
10-14 days for colony formation. After colonies formed the media was decanted and cells
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were fixed and stained at RT with 2-3 mL of 0.4-0.5% crystal violet in ethanol for 5-10
minutes. The crystal violet solution within each well is then collected with an autopipette and
returned to the stock solution for future use. Excess crystal violet solution is removed by
submerging the plates into a bucket of warm water. The plates are then tapped on a cloth
such as paper towels or laboratory wipes, inverted and placed on an absorbent bench pad, and
allowed to dry overnight before analysis. Colony counting was manually performed under a
stereomicroscope to score only colonies with 50 or more cells.

High-throughput clonogenic assay
The dispensing solution used for standard 6-well clonogenic assays was the same as
used for the 96-well high-throughput clonogenic assays. If available, the cell seeding was
performed with a semi-automated liquid dispenser such as an ELISA plate washer for
consistent and rapid cell plating. Experiments performed at MD Anderson utilized a BioTek
MultiFlo FX Microplate Dispenser. When automated dispensing options were unavailable,
cells were plated using a 12 well multichannel pipette. For the high-throughput clonogenic
assays cells were seeded at a constant 100 cells per well in a total volume of 100 µL per well.
Following cell plating, 96-well plates required a 60 minute RT incubation for sufficient cell
attachment to prevent movement when returned to culture at 37°C (97). As with the
traditional clonogenic assay method, cells were allowed to attach and stabilize in culture for
8-10 hours before irradiation. Two plates per dose level were irradiated to achieve 16
replicates per LET-dose combination. After a cell line dependent colony formation time
period (5-5.5 days for the H460 cells and 7-7.5 days for the H1437 cell line), cells were fixed
and stained with 0.4-0.5% crystal violet in ethanol. The culture media was removed using the
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“swish and flick” method. Liquids are removed by inverting the uncovered microplates over
a sink with running water and rapidly flicked in air. For the high-throughput clonogenic
method, the crystal violet solution is placed within a vessel such that at least one 96-well
microplate can be submerged for 5-10 minutes at RT. Following staining, the plate is
inverted and gentle tapped against the side of the container to remove the crystal violet
solution. The plate is then serially dipped into two buckets containing warm water to dilute
and remove the excess dye solution. Water is removed by flicking the plates in air over the
sink and then tapping the plates on absorbent cloth. The plates are then inverted and angled
on their lids for at least one day to facilitate drying prior to further analysis. High-content
automated laser confocal analysis with an IN Cell Analyzer 6000 was used to identify
colonies containing 50 cells or more. Four overlapping fields per each well in a 96-well
microplate were obtained using a 4x objective with a 0.2 numerical aperture and the IN Cell
Analyzer’s 5.5-Mp sCMOS camera (2560×2160 pixels) with a 6.5-µm pixel size. The
excitation wavelength was 640 nm (red) and the emission wavelength was 706 nm (Cy5).
The GE Developer v1.9 software was used to stitch the four fields together with a 5%
overlap creating a composite image for each entire well. Colonies and cells were identified
and masks generated from object filters of feature size and intensity. The cells were linked to
colonies, and only colonies containing 50 or more cells were scored.

Doubling time determination
Estimates for established cell line doubling times were initially determined by
literature searches. Follow up measurements were performed by plating single cell
suspensions, returning the plate to culture, and counting the number of cells present under a
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microscope at later time points such as 24 and 48 hours after seeding. The doubling time for
the H460 cell line was also measured by plating replicate flasks, counting the number of
viable cells within a replicate over a time course, and fitting the number of cells to an
exponential growth function.

SF calculation and fitting
The plating efficiency (PE) for a cell line was defined as:
𝑃𝐸 =

𝐶KLM
𝑁KLM

Where C0Gy is the number of colonies formed in the unirradiated control plate and N0Gy is the
number of cells seeded in the unirradiated control plate. The SF was determined by
normalizing the number of colonies present within an experimental condition, dose-LET, to
the average number of colonies of the unirradiated control plates:
𝑆𝐹 =

𝐶
𝑃𝐸 ∗ 𝑁

Where C and N are the number of colonies counted and number of cells seeded within a well
respectively. The limit of detection (LOD) for the clonogenic assays was defined as 1 colony
per well or an SF lower bound of 1/(N*PE). Dose levels where the averaged SF value was
lower than the LOD were omitted from analysis. The obtained data was fit to the linearquadratic equation:
𝑆𝐹 = 𝑒 ,(/0120

3)

Where D is the delivered dose and a and b are parameters to be fit by a 1/Yk weighted
nonlinear regression. An appropriate weighting factor, k, was determined following the
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method found in (98) where k is determined by performing a robust linear regression to the
logarithm of the replicate variance versus the logarithm of the replicate mean. For proton and
photon irradiated cells k was set equal to 1 and for carbon and helium ions k was set to 2.

Relative biological effectiveness calculation
Relative biological effectiveness (RBE) is defined as the ratio of doses to achieve an
isoeffect:
𝑅𝐵𝐸 =

𝐷𝑜𝑠𝑒:;<=>;?
(𝑎𝑡 𝑖𝑠𝑜𝑒𝑓𝑓𝑒𝑐𝑡)
𝐷𝑜𝑠𝑒@AB=

Where DControl is the dose of the control radiation and DTest is the experimental radiation
quality being interrogated. RBE for a given radiation quality was determined from the results
of the linear-quadratic model fit by solving for the dose required for a chosen biological
effect level using the quadratic formula:
b𝐷' + aD + ln SF = 0
𝐷=

−a + a' − 4b ln SF
2b

The RBE errors were calculated by propagating the error associated with the fitting
parameters a and b as:
𝜎Z[\ = 𝑅𝐵𝐸 ∗

𝛿D^
𝛿a^

'

𝜎a'_

𝛿D^
+
𝛿b^

'

𝜎b'
_

𝛿D`
+
𝛿a`

'

𝜎a'a

𝛿D`
+
𝛿b`

'

𝜎b'

a

32

Immunofluorescent staining of DSB markers
The temporal repair kinetics of DNA DSBs were assessed by immunofluorescent (IF)
labeling of established DSB repair protein foci formation following irradiation. Single cell
suspensions were plated into glass-bottom 96-well microplates (Matriplate) such that the
confluency at the time of irradiation was between 40 and 60%. Typically, 20,000-40,000
cells per well were seeded 8-12 hours prior to irradiation. The glass-bottom of the 96-well
plate should ideally correspond to the thickness of a No. 1.5 coverslip (160-190 µm). The
plates were irradiated using the high-throughput system and returned to culture for repair to
occur for multiple time intervals. Irradiated cells were fixed at the time points of 0.5, 2, 4, 8,
12, 18, and 24 or 30 hours following irradiation. Control plates that received no radiation
exposure were fixed at the initial and final time points. Fixation was achieved with 4%
paraformaldehyde in phosphate buffered saline (PBS) for 10 minutes at room temperature
(RT). The fixative was removed and cells were washed in PBS 3 times before short-term
storage at 4°C for the remaining duration of the experimental time course. IF staining
followed the fixation and subsequent washes of the final time point plates. Cells were
permeabilized and nonspecific antibody binding blocked by incubation with a 0.3% Triton
X-100/10% goat serum PBS solution for 2 hours at RT. For primary labeling, the cells were
incubated with unlabeled antibodies either overnight (14-18 hours) at 4°C or for 1 hour at
room temperature. 53BP1 primary antibodies used were either a murine monoclonal antibody
(clone BP13, Chemicon) or rabbit polyclonal (ab21083, Abcam). The concentration of the
primary antibody used was 1ug/ml. The antibody dilution buffer was 5% goat serum/0.3%
Triton X-100/PBS. Following primary antibody incubation, cells were washed 3 times for 10
minutes at RT with 0.1% Triton X-100/PBS. Cells were then incubated with the appropriate
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(goat anti-mouse and goat anti-rabbit) highly cross-adsorbed secondary antibody conjugated
to either AlexaFluor488 or AlexaFluor594 dye in 5% goat serum/0.3% Triton X-100/PBS at
a concentration of 1 µg/mL (1:2000, Life Technologies) for 1-2 hours at RT covered in
aluminum foil. Following secondary antibody incubation, the cells were washed with 0.1%
Triton X-100/PBS three times for 10 minutes at RT. Nuclei were labeled by incubation with
1ug/ml of 4',6-diamidino-2-phenylindole (DAPI) in PBS for 5-10 minutes RT. The plates
were then washed 3 times with PBS for 5 minutes at RT prior to addition of mounting media,
the final protocol step. Liquid removal within the IF procedure was achieved using the
“swish and flick” method. Solutions within the IF protocol were dispensed by either a 12
well multichannel pipette or semi-automated microplate liquid dispenser as quickly as
possible to ensure samples did not dry.
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Table 1. Volumes and concentrations used for IF.
Name

Solution

Volume/well [µL]

Fixation solution

4% PFA

150

Washing buffer

0.1% Triton X-100

200-300

Blocking and

0.3% Triton X-100

150-200

permeabilization buffer

10% Goat serum

Antibody dilution buffer

0.1% Triton X-100

125

5% Goat serum
Mounting media

Commercial Glycerol-based

100

(DAKO, FluoroMount-G)
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Immunofluorescent imaging of DSB markers
Plates were imaged on a Cytation5 Cell Imaging Multi-Mode Reader utilizing
automated microscopy with a 20x in air objective. The plate geometry was registered within
the platform’s Gen5 software. The imaging protocol was set to collect images at 16 locations
within each well resulting in 1536 images per glass-bottom microplate (Figure 7). The
protocol run time was approximately 4 hours per plate. The locations were set up as a 4x4
grid with 700-1000 µm spacing between each field of view (Figure 8). At each location a
default autofocus scan was performed on the blue (DAPI) channel to determine the scan
height (Figure 9). Three images were then sequentially captured corresponding to the
fluorescently labeled components in the blue (nuclei), green (foci), and red (foci) channels
(Figure 10, Figure 11). The images were then exported for analysis.

Immunofluorescence data analysis
The general procedure to determine the average number of foci per nucleus was to
identify DAPI-labeled nuclei and DSB-repair protein foci as image masks and quantify the
number of nuclei-associated foci using CellProfiler 2.2.0 (Broad Institute) (Figure 12). The
modules and the settings used in the CellProfiler pipeline for the foci analysis are shown in
Figure 13 to Figure 23. The settings were manually benchmarked by eye on a subset of the
captured images.
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Figure 7. Cytation5 software procedure tab.
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Figure 8. Cytation5 setup for automated imaging.
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Figure 9. Cytation5 setup for the blue channel.
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Figure 10. Cytation5 setup for the green channel.
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Figure 11. Cytation5 setup for the red channel.
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Figure 12. Overview of CellProfiler workflow for foci scoring.
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Figure 13. CellProfiler setup parameters for nuclei detection.

43

Figure 14. CellProfiler setup parameters for nuclei expansion.
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Figure 15. CellProfiler foci filter for red channel setup.
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Figure 16. CellProfiler foci filter for green channel setup.
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Figure 17. CellProfiler foci red channel mask setup.
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Figure 18. CellProfiler foci green channel mask setup.
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Figure 19. CellProfiler measurement parameters to score green foci.
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Figure 20. CellProfiler measurement parameters to score red foci.
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Figure 21. Selecting type of measurements for objects detected with a CellProfiler pipeline.
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Figure 22. Correlating measurements between objects in CellProfiler.
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Figure 23. Exporting data in CellProfiler.
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3D Cell Culture

Glioma stem cell (GSC) lines and media
Patient-derived GSCs were obtained from Dr. Erik Sulman. The GSCs are cultured in
Neural Basal Medium (NBM) consisting of DMEM/F-12 media, 10% B-27 serum-free
supplement, EGF (20 ng/ml), FGF (20 ng/ml), and 1% normocin in a humidified incubator at
37°C and 5% CO2. GSC cell lines used for this work were GSC23, GS7-11, and GSC300.

GSC maintenance and culturing
In the absence of serum GSC cultures grow in vitro as a spheroidal suspension.
General GSC maintenance consisted of monitoring cultures for pH-dependent media color
change and neurosphere formation. NBM was refresh once it took on a yellow color due to
the solution becoming acidic as indicated by the pH indicator, phenol red. Media changes
were achieved by transferring the cell suspension solution into a sterile conical tube, washing
the stock T-75 flask with 5mL of serum free media (SFM; DMEM/F-12 media with no
additives) and placing the wash volume into the tube. The cell suspension is then centrifuged
for 5 minutes at 1300 rpm at RT. Following centrifugation, the supernatant is removed, the
cell pellet is resuspended in fresh NBM, the solution is transferred into a tissue culture flask,
and the flask is returned to the incubator. Once neurospheres have formed within a culture,
the cell line must be passaged by forming a single cell suspension and subculturing the cells.
Passaging the GSCs follows a similar procedure to a media change. All steps are performed
at RT. The cells are collected and centrifuged at 1300 rpm for 5 minutes. The supernatant is
aspirated and the cell pellet is resuspended in 2 mL of 0.05% trypsin-EDTA and incubated at
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37°C for no more than 2 minutes. Trypsinization is then halted by the addition of an equal
volume of defined trypsin inhibitor and mixing the solutions with additional pipetting. 11 mL
of SFM is then added to the cell solution and a single cell suspension is created by further
pipetting of the solution (3-12 times). The cell solution is then centrifuged at 1300 rpm for 5
minutes after which the supernatant is removed and the cell pellet is resuspeneded in NBM.
The single cell stock solution is then diluted into a new tissue culture flask with additional
NBM. Typical split ratios are 1:2-1:5 depending on the confluency of the original flask.

GSC spheroid formation
Uniform spheroids were formed by adding an appropriate number of GSCs to
microplates conducive to spheroid formation. GSCs were collected, trypsinized, and
resuspended to form a single cell suspension. The cell concentration was determined and the
stock solution was diluted to make a plating solution with a concentration of 5 cells per µL.
200 µL per well of the plating solution was then dispensed into ultra-low attachment round
bottom plates to achieve 1000 cells per well. The round bottom plates were then centrifuged
for 5 minutes at 200g at RT to promote cell aggregation. Following centrifugation, a sample
of the wells are examined utilizing a light field microscope to ensure cell clustering. If further
aggregation is required, the plates may receive additional centrifugation. The cell aggregates
are returned to culture for at least 3 days for spheroid formation to occur. Following the
initial incubation period, the wells are examined under a light field microscope to ensure
spheroid formation prior to use.
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Rat brain microtissues (RBMTs)
The normal brain tissue organoid system utilized was developed by and available precommercially from InSphero, Inc. In this model complete neonatal rat brain tissue is
harvested and homogenized. The homogenate is coalesced into spheroids above a low
adhesion 96-well plate (GravityTrap) utilizing a modified hanging drop method that yields
one organoid per well. The resulting RBMT organoids have been found to be suitable for
long-term culturing (>3 months) while exhibiting composition and maturation analogous to
native tissue.

Rat brain microtissue receiving and culturing
Once spheroid formation is completed and passes quality assurance testing including
viability and size measurements, the maintenance culturing media is replaced with a shipping
media. The wells of each plate are sealed with a sterile silicone insert, the plate is lidded, and
then each plate is individually sealed within a plastic microplate bag. The tissues are shipped
in an insulated container with heat packs and electronic temperature monitoring to ensure
tissue viability. When the RBMT package arrived, the temperature log files were accessed
and examined for any threshold alarms. With no temperature alarms present, the tissue media
was visually inspected for abnormalities such as indications of contamination or evaporation.
If no concerns were noted with the delivery inspection, the tissues were then prepared for
maintenance culture. The RBMTs are shipped with a buffered media that does not require
CO2. The shipping media must be exchanged with the maintenance media for traditional
culturing in a humidified incubator at 37°C and 5% CO2. This media change is achieved by
first removing the outer plastic seal of each plate and inverting each plate 5 times. The plates
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are then centrifuged at 200g for 2 minutes at RT. The RBMTs are then moved back to a
biological cabinet to remove the silicone well sealer by firmly holding the plate down with
one hand while the other hand slowly peels the sealer with uniform pressure starting from
one end of the plate. The shipping media is removed using a multichannel pipette by angling
the tips along the edge of the wells and slowly (approximately 30 µL/s) aspirating the
majority of the shipping media (90 µL). Once the shipping media is removed, 75 µL per well
of warm maintenance medium is dispensed with the multichannel pipette. The plates are relidded and the spheroid morphology is visually examined under a light field microscope. The
plates are then placed in a humidified incubator at 37°C and 5% CO2 to recover and
normalize overnight. RBMTs plate scans are acquired the following day to measure spheroid
sizes.

RBMT replating
If necessary, the tissues are separated into different plates to be exposed to the desired
experimental conditions. Wells of the plates receiving RBMTs are prefilled with 100 µL of
maintenance media and wells to not be experimentally utilized are filled with 200 µL of PBS.
The plates are then placed in an incubator for 15 minutes before the replating commences.
The transfer microplates were the same ultra-low attachment 96-well round bottom plates as
those used for the GSC spheroid culturing and irradiations. Replating the RBMTs is achieved
using large bore or orifice 200 µL pipette tips. The tip is placed to cover most of a well
opening and 50 µL of media is siphoned with sufficient speed to draw in the spheroid. The
tip is visually examined after each aspiration to ensure that a spheroid is contained within the
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media. The 50 µL of media containing the spheroid is then transferred to the appropriate prefilled well. Once a transfer plate contained all required spheroids, it was re-lidded and held
slightly above eye level such that the well bottoms could be visualized to confirm the
presence of spheroids within each well. The microplates are then placed in a humidified
incubator at 37°C and 5% CO2 to recover and normalize for at least 8 hours before
experimental use.

Spheroidal culture media refreshment
For long term culturing (>3-5 days), both GSC and RBMT microplate spheroid
cultures require that the medium be intermittently refreshed. Media changes were performed
by placing the tips of a multichannel pipette against the well edges and sliding the tips down
approximately half the height of the wells while avoiding the well bottoms. Half the media
volume was then slowly removed. For the RBMTs and the first two weeks of GSC spheroid
cultures media changes were performed every 3-5 days. The GSC spheroid cultures require
increased media change frequency as they grow as indicated by the phenol red pH indicator
present in the media.

Spheroid high resolution scans
Spheroidal culture size measurements were taken at 4800 dpi on a Cell3Imager
flatbed scanner. The focal plane of the scanner is adjustable and required optimization by
brand for each tissue culture plate utilized. The value for the Corning 96-well round bottom
ultra-low adhesion plates used was 13.00 mm. Insphero GravityTrap plates required 2
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imaging heights, one for the plate center and the other for the peripheral wells. Using a plate
map, the outer wells scan height was set to 13.85 mm and the inner wells were scanned at
13.70 mm.

Spheroid size measurements
Following the capture of a high-resolution scan, spheroid size was determined using
image based analysis and the Cell3Imager analysis software package. Prior to analysis, the
scanned image is segmented into individual well images using the well spacings defined
within the respective plate geometry file. A region of interest within the well area is then
defined for analysis. The recipes used to measure the spheroid size of the spheroids were user
trained algorithms. The scanner software settings as well as the size measurement recipe are
shown in Figure 24Figure 34.
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Figure 24. Cell3Imager scan setup.
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Figure 25. Cell3Imager high-resolution plate scan.
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Figure 26. Cell3Imager well center orientation.
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Figure 27. Cell3Imager well segmentation.
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Figure 28. Cell3Imager spheroid measurement.
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Figure 29 Cell3Imager size measurement pre-processing parameters.
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Figure 30. Cell3Imager size measurement object detection parameters.
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Figure 31. Cell3Imager size measurement live or dead detection parameters.
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Figure 32. Cell3Imager measurement window.
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Figure 33. Cell3Imager measurement window with scored spheroids displayed.
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Figure 34. Cell3Imager plate information window.
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3D surviving fraction calculation
Surviving fractions of clonogenically immortal cancer spheroid cultures were
determined from a longitudinal series of size measurements over a time period of 30 days by
adapting the method of Demidenko (99). Demidenko demonstrated SF can be determined
from tumor size measurements as:
𝑆𝐹 = 𝑒

,b∗@L0

Where k is the growth constant and TGD is the tumor growth delay. The growth constant is
calculated by fitting the size of the unirradiated control condition to the exponential growth
equation:
𝑆𝑖𝑧𝑒 = 𝑒 b∗=
The TGD is the time difference for an unirradiated tumor and an irradiated tumor to reach
iso-response. For this work the response level was set to be when the average tumor
spheroids’ volume increased by a factor of 16 from the initial size. TGDs were calculated
using linear interpolation between measured spheroid sizes.
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Figure 35. Demonstration of TGD determination. TGD is experimentally determined using
linear interpolation from the measured growth curves.
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Viability
Spheroid viability was assessed using the Realtime-Glo MT Cell Viability Assay, a
non-lytic bioluminescent reporter assay which enables real time viability monitoring. The
assay consists of two reagents: a luciferase-based additive and a cell permeable, pro-substrate
form of luciferin. Both reagents are added to the culturing media. The pro-substrate is
reduced to luciferin within viable cells and released from the cells into the surrounding tissue
culture media. The reduced pro-substrate is rapidly used by the luciferase media additive to
produce a bioluminescent reaction and thus signal. The assay has the benefit of being nontoxic enabling additional assays on the spheroids such as terminal histology and
immunofluorescence staining. Caution must be exercised when using this assay as the
readout is dependent on the sample metabolism and thus temperature.

RBMT immunofluorescent staining
RBMTs were transferred into the wells of a standard 24-well tissue culture plate
using the same method as during replating. Replicate tissues were placed within the same
well. 1 mL of 4% PFA in PBS was added to each well to fix the RBMTs. The plate was
placed on a laboratory rocking platform for 45 minutes at room temperature for fixation to
occur. The fixative was removed by carefully pipetting as much of the solution as possible
(typically 900-950 µL) while avoiding the microtissues. Specifically, liquid removal between
steps was performed by tilting the plate between 30° and 45° and placing the tip of a 1 mL
pipette at the bottom edge of the well near the superior portion of the well (i.e. where the
liquid is least thick when the plate is tilted) and siphoning the solution while moving the
pipette along the bottom edge. As the volume reduces, the tissues will begin to move with the
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solution towards the tip. When the tissues begin to move, the pipette should be moved to the
other side of the well, the plate tilted away from the tip, and any additional solution that can
be removed should be pipetted while the tissues move towards the tip again. Once the
fixative is removed, the tissues are then washed with 1 mL of PBS with rocking four times at
RT for 10 mins. The RBMTs are permeabilized with 1 mL of 1% Triton X-100 in PBS for 1
hour with rocking at RT. The tissues are then blocked for 2 hours with rocking at RT with 1
mL per well of 10% goat serum/0.3% Triton X-100/PBS. The primary antibody incubation
was performed overnight at 4°C with rocking. The antibodies were diluted in 5% goat
serum/0.3% Triton X-100/PBS. Each well contained 500 µL of primary antibody solution.
The primary antibody used to label neurons was a rabbit polyclonal to beta III tubulin
(1:1200, Abcam, ab18207). Glial cells were labeled by a chicken polyclonal antibody to glial
fibrillary acidic protein (GFAP) (1:2400, Abcam, ab4674). Primary antibody concentrations
were typically 1 µg/mL. After the primary incubation, the RBMTs were washed four times
using 1 mL per well of 0.1% Triton X-100/PBS for 20 minutes each at RT with rocking. The
spheroids were then stained overnight at 4°C with rocking. 500 µL per well of highly crossadsorbed goat anti-rabbit and goat anti-chicken secondary antibodies respectively conjugated
to AlexaFluor488 and AlexaFluor594 dye diluted in 5% goat serum/0.3% Triton X-100/PBS
at a concentration of 1 µg/mL (1:2000, Life Technologies) was used for the secondary
staining. During the secondary antibody incubation and all the following steps the plate was
wrapped in aluminum foil to protect the fluorescent dyes from light. Following secondary
antibody incubation, the cells were washed with 0.1% Triton X-100/PBS four times for 20
minutes at RT. If an optional nuclear staining was performed, the RBMTs would be
incubated while protected from light with 1 mL of DAPI (1µg/mL) per well for 60 mins at
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RT with rocking. The RBMTs are washed an additional three times with 0.1% Triton X-100
for 10 minutes at RT with rocking. Following the IF staining protocol, the RBMTs were
mounted on 8-well chamber slides with replicate tissues placed within the same well. A cut
200 µL pipette tip was precoated in serum and then used to manually transfer the RBMTs
from the 24-well plate to the appropriate well on the chamber slide without the use of a
pipette. Transferring tissues without a pipette was achieved by holding the pipette tip with
the thumb and the middle finger so that the index finger can access the open top end of the
tip. Adjusting the pressure applied to the top of the tip when submerged will generate
suction. The RBMTs were first visualized under a light microscope. The pipette tip was
placed adjacent to the tissues, and the pressure within the tip was reduced to create suction to
draw in the tissue. The pipette tip is then placed at the appropriate location on the chamber
slide and pressure is applied to expel the liquid and RBMT. The transfer process is repeated
for all conditions. Once all the desired RBMTs were transferred to a chamber slide, a drop of
mounting media (20-25 µL) was applied to each well. The slides were covered with a No.1
glass slide, protected from light, and allowed to set overnight. The next day coverslip edges
are sealed with clear nail polish. The sealed slides are protected from light and placed at 4°C
for storage.

RBMT immunofluorescent imaging
RBMT confocal imaging was performed using an Olympus IX83 microscope with a
60x oil immersion objective. RBMT imaging consisted of four 512x512 pixel fields forming
a rectangle (2x2) to capture the entire spheroid. The image plane spacing was set to 0.5µm
and the total stack height was adjusted to capture an entire spheroid. The microscope pin hole
size was set to 80 µm. The pixel dwell time was 2 µs. Laser parameters were 0.3% blue (473
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nm) laser power and 1.2% green (543 nm) laser power. The gain was set to 475 V for the
green channel and 600 V for the red channel. Kalman 2x averaging was used per line. Each
image was captured sequentially to prevent spectral cross over.

RBMT image analysis
Maximum intensity projection images of each RBMT field stack were stitched to
create a single composite image per RBMT using the Fiji package of ImageJ. The
Grid/Collection addon was used to perform a row by row, right and down, linear blend fusion
(100). The composite images were scored by thresholding the channels and calculating the
integrated pixel intensity. The thresholds were determined from the control conditions. For
both the red (beta-III tubulin) and the green (GFAP) channels the thresholding range was set
to be 30 to 255.

RBMT histology
RBMTs were transferred and replicates pooled into 1.5 mL microcentrifuge tubes.
Tissues were allowed to settle at the bottom of the tube. A quick spin in a tabletop centrifuge
was performed prior to media removal to ensure tissues were settled. Excess culture media
was removed by inserting a 200 µL pipette tip at the liquid surface, slowly releasing plunger,
and moving the tip down the tube with the decreasing media level. The aspiration is stopped
when the spheroid cluster begins to be disturbed by the liquid removal. 500 µL of 4% PFA in
PBS is added to each tube for spheroid fixation. The fixation conditions are rocking at RT for
60 minutes. Following fixation, the fixative is removed as before, and the spheroids are
76

washed three times in PBS for 10 minutes each at RT with rocking. Organoids are then
removed from the microcentrifuge tube using a pipette with a wide-bore tip and placed
within a droplet on a piece of parafilm. Excess PBS is removed by touching the droplet with
the edge of an absorbent cloth such as a Kimwipe. The tissues should be present on the
parafilm with little liquid surrounding them. The fixed tissues are then embedded in 2%
agarose/PBS by dispensing a small droplet over the RBMTs. The agarose is allowed to cool
until solidified at which time it is removed from the parafilm and placed within a histological
cassette containing pre-wetted sponges. The cassettes are submerged in 70% ethanol
requiring that they are labeled with pencil. The container holding the histological cassettes is
then submitted to the core facility for standard histological processing with the directions to
embed the agarose plugs with the flat end at the top of the paraffin block.

Statistical analyses and plotting
Statistical analyses and plotting were done using GraphPad Prism 7.0. SF data are
shown on a semilog scale as mean ± standard error of the mean (SEM). Data were fit using a
weighted, nonlinear regression to the linear-quadratic model. The extra sum-of-squares F test
was used to compare clonogenic survival curves as a function of LET. The foci data and
GSC growth curves are shown as mean ±95% confidence interval. SFs calculated for GSCs
are presented as mean ± standard deviation (SD). RBMT size, viability, and relative
expressions are presented mean with replicates. RBE standard errors were calculated by
propagating the standard error of the α and β fits.
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Results

Development of a high-throughput irradiation platform
The development of the high-throughput irradiation system was initiated by the desire
to apply high-throughput clonogenic assays towards particle radiation biology studies with a
focus on improving the statistical power and speed of traditionally laborious studies (Figure
36). As opposed to the traditional clonogenic assay typically performed in 6-well plates, the
high-throughput clonogenic assay utilizes a 96-well microplate plate increasing the number
of replicates by a factor of 16. The readout of the high-throughput clonogenic assay in our
studies is performed using an automated high content screening system (IN Cell Analyzer
6000) to image the wells and perform colony identification and scoring (Figure 37). The use
of automation with the clonogenic assay results in a shorter turnaround time from colony
staining to data analysis and results.
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Figure 36. Traditional vs high-throughput clonogenic assays. The clonogenic assay is
typically performed in 6-well plates (top). A 96-well microplate contains 16 times more data
wells. Qualitatively, the colonies and their distributions within the wells for the two setups
appear similar. Image reproduced from (11).
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Figure 37. Image analysis workflow for the high-throughput clonogenic assay. The general
image analysis for the high-throughput clonogenic assay consists of imaging the wells in four
quadrants with a 4x objective followed by stitching the images together to form a complete
image of each well. A size and threshold filter is applied to the image to create colony masks.
Within the colony mask, a sieve filter is applied to determine the number of cells contained
within each colony. Colonies with more than 50 cells are scored as viable. Image reproduced
from (11).
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To apply the high-throughput clonogenic assay towards the study of proton biological
response, we interposed a multi-tiered pattern of material between the 96-well microplate and
the proton beam (Figure 38). This design enabled the sampling at 12 different locations along
the beam path by aligning the steps of the material with the columns of the 96-well plate
resulting in 8 replicates per condition per plate.
A calibrated Geant4 Monte Carlo simulation of The MD Anderson Proton Therapy
Center’s 79.7 MeV proton beam in water was performed to calculate the relative dose and
LETs for a 5 µm target size along the beam path (Figure 6 left, Figure 39). 12 locations along
the dose-deposition profile were sampled by the high-throughput irradiation apparatus.
Lucite, the material used for compensators at the Proton Therapy Center, was chosen to
construct the jig necessitating the determination of the water equivalent thickness of Lucite to
match the desired depths. The high-throughput irradiation apparatus was milled out of a
single Lucite block using a high precision CNC machine (Figure 40). The setup directly
inserts into the proton therapy snout with the proton beam incident from below. The
microplate sits on top of the jig. A plate holder was fabricated to ensure plate positioning
such that the columns align with the respective Lucite steps.
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Figure 38. Concept of a variable range shifter for high-throughput irradiations. The general
concept used for high-throughput irradiations is the design of a multi-tiered plate holder.
Altering the thickness of the steps samples different locations along the beam. Aligning the
steps of the holder with the columns of a 96-well microplate results in a single dose-LET
combination delivered to each well within the column per irradiation. A standard 96-well
plate has 12 columns indicating 12 locations along the beam can be sampled with 8
replicates for each dose-LET combination. Image reproduced from (11).
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Figure 39. Simulated proton beam in Lucite used to select sampling locations. Monte Carlo
simulations were performed to determine the dose deposition profile (red) and corresponding
(LETs) along a 79.7 MeV proton beam at the PTC. Using these simulated results as a guide,
the corresponding thickness of Lucite required to sample a dose-LET combination was
determined. The points along the curves demonstrate the sampling locations for the initial
Jig design. Image reproduced from (11).
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Figure 40. Physical setup for high-throughput irradiations. The high-throughput irradiation
apparatus was constructed from a Lucite block with a high-precision and high-accuracy
milling machine. The Jig was designed to directly insert into the snout of the proton gantry to
facilitate reproducible setup. The biological samples sit on top of the holder and are
irradiated from the bottom of the plate.
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Once the jig construction was completed, the dose peak of the system was calibrated
by irradiating a stack of EBT3 films placed on top of the setup. The films were scanned, and
the dose peak was found to fall within the thickness associated with column 9 in between
films 3 and 4 of the stack indicating the need to insert 3 EBT3 films below the 96-well plate
during irradiations to achieve a dose peak in column 9 (Figure 41).
The physical irradiation geometry (beam line, jig, EBT3 films, 96-well plate, etc.)
was modeled and proton radiation exposure simulated in Geant4 to determine the doses and
LETs a layer of adherent cells are exposed to for each column thickness. Cell thickness has
been reported to range between 3 and 7 µm. For the high-throughput irradiation setup, the
cell layer is modeled as a 5 µm water layer. The simulations of the physical setup were in
good agreement with expectations. The doses were found to rise with increasing depth until
the peak dose in column 9 after which they dropped off (Figure 42). The LETs were found to
continually increase with the sampling depth. The rate of LET increase is initially slow until
the proximal portion of the Bragg peak at which point there is a rapid increase in the LET as
the protons begin to stop.
The Monte Carlo simulations were validated by intermittent ionization chamber
measurements placed above the high-throughput setup. The Monte Carlo predictions and ion
chamber measurements were consistently found to be within 1% (11).
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Figure 41. Relative jig doses from film measurement. The relative doses of the highthroughput setup were determined by placing a stack of EBT3 on top of a 96-well plate and
performing an irradiation test. The films demonstrated a dose peak in column 9 between
films 3 and 4 of the stack. It was thus decided to insert 3 films below the plate for all
irradiations to shift the dose peak of the beam into column 9. For all clonogenic irradiations
using the initial Jig design, three EBT3 films were placed underneath the irradiated 96-well
plates. It should be noted that the same 96-well plate design from a single manufacturer was
used for all clonogenic experiments at MDA. Image reproduced from (11).
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Figure 42. Relative doses and LETs calculated for the physical setup of the initial Jig. The
doses and LETs received for column of the 96-well plate were determined by simulating the
experimental setup utilized (Figure 6). Image reproduced from (11).
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A new jig was developed after gaining experience with the design, construction, and
implementation of the initial jig (Figure 43). The updated setup was able to hold two plates
simultaneously further increasing the irradiation throughput by a factor of 2 over the initial
design. The updated jig was also designed to be more flexible with regards to the irradiation
orientation. Many ion therapy centers make use of fixed horizontal beam lines to remove the
large costs associated with gantry-based systems. Experimental beam lines found within
many ion therapy centers also frequently consist of a fixed horizontal beam line. The liquid
surface tension of the cell culture media in a 96-well plate was found to be sufficient to
prevent spillage at any plate orientation as long as the plate was handled gently (Figure 44).
The second high-throughput irradiation setup was thus able to be placed in either a horizontal
or vertical orientation.
The initial jig design was found to sample low LET protons (1-5 keV/µm) in 8 out of
the 12 columns with 7 out of the 12 columns sampling LETs between 1 and 3 keV/µm.
Given the range of proton LETs typically simulated for in vitro experiments being between 1
and 20 keV/µm, our team designed the next jig to evenly sample proton LETs over the entire
range. In particular, the design goal was to achieve a biological response measurement for
every 1-2 keV/µm proton LET increment. Following the previously developed methodology,
an 81.4 MeV proton beam was simulated in water to determine material thickness for the
desired LET samplings (Figure 45). The next version of the high-throughput irradiation
apparatus setup was simulated to calculate the dose and LET the cell layer in each column
would be exposed to. The new jig simulations results indicated that the new jig evenly
samples the proton LETs over the range of 1-20 keV/µm (Figure 46, Table 2).
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Utilizing similar methodology to the proton setups utilized at the MD Anderson
Proton Therapy Center, high-throughput irradiation setups were designed for heavier ions
(helium, carbon, oxygen) available at the Heidelberg Ion Therapy (HIT) Center.
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Figure 43. Physical setup for high-throughput irradiations with second Jig design. Following
the experience obtained with the initial high-throughput irradiation apparatus design,
several changes were made in the second version of the high-throughput irradiation
apparatus. Irradiation throughput was further improved by a factor of 2 by adding the ability
to hold two plates per irradiation. The second design also included a flexible irradiation
orientation (horizontal and vertical).
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Figure 44. Surface tension in a 96-well plate. The surface tension present within a standard
96-well microplate with round wells is sufficient to prevent the culture media from spilling
out at any plate orientation assuming the plate does not experience a large acceleration. For
96-well plates with square wells, the media can be contained using plate sealers.
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Figure 45. Simulated 81.4 MeV proton beam in Lucite used to select sampling locations for
second Jig design. The focal design alteration for the second high-throughput irradiation
apparatus was the increased LET sampling in the range of 5-20 keV/µm (triangles).
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Figure 46. Relative dose and LETs per column in the second Jig design. The experimental
setup of the second version of the Jig was designed to not require film shims underneath the
sample plates. The MC simulation of the experimental setup predicated an even sampling of
LETs over the typical experimental range of 1-20 keV/µm. The LET was found to increase
with increasing column number (and corresponding Lucite step depth). The dose peak was
found to be in column 7.
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Table 2. Calculated LETs for each proton jig version.
Jig Version:
Column
1
2
3
4
5
6
7
8
9
10
11
12

1.0

2.0
LET [keV/µm]

1.0
1.2
1.6
1.9
2.0
2.5
3.3
5.1
11.0
14.8
17.0
18.3

0.9
2.5
4.1
5.8
6.7
8.5
10.6
12.1
13.5
14.9
16.8
18.0
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Optimizing the high-throughput clonogenic assay

Fixation timing for optimal colony scoring
The automated scoring algorithm initially uses a size and intensity filter to detect and
create a colony image mask of objects present within each well (Figure 37). A cell filter is
then applied to determine the number of cells within each object and only those with at least
50 cells are scored as viable colonies. Given the automated scoring algorithm and limited
space available for growth within a 96-well compared to a 6-well plate, the timing of colony
fixation plays a crucial role in determining data quality. The optimal fixation time allows for
colonies to be both detected and scored while avoiding overgrowth and clumping loss on
colony scoring (Figure 47). The assay requires that cells have sufficient time to form a
colony of 50 or more cells requiring a minimum of 5.5 doublings. If colonies are fixed prior
to reaching 50 cells, they will be detected but not scored as viable by the detection algorithm.
If the colonies are allowed to overgrow on the available surface area, adjacent colonies will
begin to impinge on one another causing errors in automated colony counting. In effect this
artifact translates to an increased scoring efficiency but an absolute decrease in colony
detection.
The fixation time point for optimal colony scoring is thus cell line dependent based
on the cell line’s doubling time as well as colony size and number of cell seeded per well.
The doubling time for each cell line can be used as a guide for the appropriate minimum
fixation time point post-seeding, but the optimal conditions must be verified by performing
an initial control time course experiment of colony formation for each cell line to be used in
the high-throughput assay.

95

Colonies

80

Detected
Scored

60
40
20

6

5

4

6

5

4

0

Time to fixation [d]
Figure 47. Automated colony detection and scoring for H460 cells. The automated detection
and efficient scoring of colonies in the high-throughput clonogenic assay requires cell line
specific optimization. With the limited growth area present within the well of a 96-well
microplate, colonies can easily merge and not be algorithmically declumped if the fixation
time point is too late resulting in a reduction in colony detection (day 6). Alternatively, early
fixation results in colony detection but reduced viable colony scoring due to a lower cell
number per colony detected (day 4). The optimal fixation and staining time point for the
assay is when the number of scored colonies is a maximum (day 5).
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Incubator effects
An undesirable variability in seeding uniformity was noted in the initial experiments
for the high-throughput clonogenic assays. In particular, the effect was frequently observed
in the outer wells of the 96-well microplates. The affected wells exhibited colony merging
along their periphery preventing individual colonies from being distinguishable even by the
human eye. It was determined that this clumping effect was due to uneven cell seeding and
was ultimately attributable to a temperature-sensitive edge effect. Uniform distribution of
cells within all wells was thus achieved by allowing the cells to attach for 60-90 minutes at
room temperature on the benchtop.

Addition of a limit of detection
As expected, the initial results from the high-throughput clonogenic assays
demonstrated a decreasing surviving fraction with increasing dose (Figure 48). However, we
observed instances where the SF would decrease to a relative minimum, then slightly
increase, and finally further decrease with dose but with a shallower slope. Fitting the
conditions with this effect to the linear-quadratic model resulted in poor or impossible
weighted fits by non-linear regression. Examining the wells exposed to the highest dose
(20Gy) and comparing the colonies to control conditions revealed that no colonies were
actually present indicating that cell clusters and giant cells were incorrectly being scored as
viable colonies (Figure 49). The uncertainty associated with measurements of low SF
conditions were also noted to increase with decreasing SF conditions due to the inclusion of
replicates with SFs of 0.
These observations lead to the conclusion that the application of a limit of detection
(LOD) was needed to circumvent the addition of artefactual signals in the high-throughput
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clonogenic assay results (Figure 50). If all cells seeded form a colony, the SF LOD is
theoretically 1/N where N is the number of cells seeded within a well. For example, with 100
cells seeded, the SF LOD is 1/100 = 0.01. However, as the readout within the clonogenic
assay is the CFU, the LOD must be adjusted to account for the number of CFUs as each cell
seeded will not necessarily form a colony. As such, the SF LOD for a given experiment was
defined as:
𝐿𝑂𝐷 =

1
1
=
𝐶𝐹𝑈(0𝐺𝑦) 𝑁 ∗ 𝑃𝐸

Where N is the number of cells seeded within a well and PE is the plating efficiency of the
cell line determined under control conditions. Once a given condition reached the
experimental LOD, the further SF data was excluded from analysis (Figure 51). The LOD
application was found to remove the artefactual trends observed for SF as it approached the
LOD. The resulting data was found to fit the LQ model well (Figure 52).
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Figure 48. Raw surviving fraction data from a high-throughput experiment. The LQ model
did not fit the data generated. It was noted that the SFs would drop with increasing doses to
an SF of approximately 0.01. At this SF value the results for each condition would frequently
present an altered trend such as an increase in SF before further reduction with dose or a
slower rate of SF reduction.
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Figure 49. Colony types present in the clonogenic assay at 20x magnification. Altered
cellular morphology following irradiation with highly biologically active radiation (doseLETs) was observed in the stained colonies under a bright-field microscope. Highly damaged
cells were generally larger than undamaged cells and giant cells were frequently noted. It
was determined for low SFs these combined effects were errantly being scored as viable
colonies resulting in spurious results at low SFs.
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Figure 50. Visualization of the limits of detection. To eliminate the background present
within the clonogenic assay, a limit of detection (LOD) was applied to the SF data. The LOD
value is calculated for each experiment by determining the number of colony forming units
seeded into each plate.
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Figure 51. Clonogenic SF results following LOD application. Once the SF for a given
condition falls below the LOD determined for the experimental run, the following values are
excluded from further analysis.
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Figure 52. LOD applied HT clonogenic data over appropriate axes ranges. With the
application of a LOD, the results from the high-throughput clonogenic assay are well
modeled by the LQ model using a weighted-nonlinear regression fit.
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Benchmarking traditional vs high-throughput clonogenic assay
The high-throughput clonogenic assay was benchmarked against the traditional
clonogenic assay manually performed in 6-well plates for the H460 cell line. Cells were
seeded, allowed to attach and normalize before exposure to gamma photons produced from a
Cs-137 source. Plates from each clonogenic method were simultaneously irradiated for each
dose level. After 5 days the high-throughput clonogenic plates were stained and submitted for
automated analysis. The traditional method plates were allowed to form colonies for 12 days
before staining and manual scoring. SFs were calculated from the results. Qualitatively, the
SF values appeared to be in good agreement. Both conditions were fit by a weighted, nonlinear regression to the linear quadratic equation. The resulting fits were found to be not
statistically different by the extra sum of squares F-test (Figure 53).
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Figure 53. Benchmarking of HT versus manual clonogenic assay. The H460 cells were
seeded in either 6-well or 96-well plates, irradiated in a Cs-137 biological irradiator, and
then subjected to either the high-throughput or traditional clonogenic assay. The results of
the assays underwent SF analysis with subsequent 1/Y-weighted fitting to the LQ model. The
fits were found to be not statistically different via the extra sum-of-squares F test. Error bars
are standard error of the mean (SEM). Reproduced from (11).
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High-throughput clonogenic assay results for adherent cells

Control radiation: photon SF and RBE
H460 cells were prepared and subjected to the high-throughput clonogenic following
exposure to photon radiation of different energies. The photon sources used were a Cs-137
biological sample irradiator and a clinical Varian linear accelerator. The photon energies
tested were 6 MV and 18 MV for the linear accelerator. Cs-137 produces gamma photons
with an energy of 662 keV. Following exposure to a range of doses, cells were allowed to
form colonies for 5-5.5 days before staining and fixation followed with subsequent data
readout using the high-throughput microscope. The results from the photon experiments
indicated a differential survival response dependent on experimental conditions (Figure 54).
Exposure to higher photon energies resulted in increased SF for a given dose. The SF results
were fit to the LQ model to facilitate RBE calculation (Table 3). The 18MV photon condition
was set as the control radiation as it demonstrated the highest SFs. The RBEs were calculated
for three biological endpoints: SF levels of 0.5, 0.1, and 0.01 (Figure 55). When normalized
to the 18MV condition, the RBEs for Cs-137 were found to be 1.17, 1.10, and 1.08 at SFs of
0.5, 0.1, and 0.01 respectively. The 6MV RBEs were found to be 1.06, 1.05, and 1.05 for the
SFs of 0.5, 0.1, and 0.01 respectively.
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Figure 54. H460 Photon SF for different sources. Cells were prepared for the highthroughput clonogenic assay and exposed to photons from a preclinical biological irradiator
with a Cs-137 source, and 6 MV and 18 MV x-rays from a clinical linear accelerator. SF and
LQ model fitting to the clonogenic data was performed. Lower SFs were observed for
irradiation with photons of lower energy. Error bars represent the 95% confidence intervals.
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Figure 55. H460 RBE for Cs-137, 6 MV, and 18 MV photon sources. RBEs for Cs-137 and 6
MV were calculated from the results of the high-throughput clonogenic assay performed with
photons produced from Cs-137, 6 MV, and 18 MV. Results were normalized to the 18 MV
results because this condition resulted in the least cell kill of all the tested radiations. Both
Cs-137 and 6 MV photons were found to have larger biological effects than 18 MV photons
with Cs-137 have the largest effects. These results indicate differential biological response
with photon energies for the H460 cell line. Additionally, they highlight the importance of
considering the type of control photon radiation used when comparing RBE results. Error
bars represent the standard error (SE).
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Table 3. Fitting parameters and RBEs for H460 photon exposures.

a
b
RBE

SF

0.50
0.10
0.01

Cs-137
0.1242
0.1115
1.17
1.10
1.08

6 MV
0.06452
0.1149
1.07
1.05
1.05

18 MV
0.04727
0.1071
1
1
1
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Particle irradiation surviving fractions
Proton
Jig 1.0
Using the initial jig design, the biological response of H460 and H1437 NSCLC cell
lines was measured at the selected jig depths using a 79.7 MeV proton beam and the highthroughput clonogenic assay (Figure 56,Figure 57). For both cell lines, the SF was found to
decrease with increasing dose for all LET samples tested. SFs were found to decrease more
rapidly with exposure to protons of increasing LETs. This effect was especially prominent
for columns sampling LETS above 11 keV/µm, the value associated with the dose peak. In
the context of the high-throughput irradiation apparatus, the term “dose peak” denotes the
column simulated to have the largest relative dose. This value is the closest value to the
Bragg peak that is sampled, but it does not necessarily coincide with the actual Bragg peak.
The SF data were fit to the LQ model with resulting fitting parameters shown in Table 4. The
a and b fitting parameters were both found to increase with irradiation with protons of
increasing LET. The ratio of a and b was found to decrease with increasing LET. The control
radiation used for most experiments was from a preclinical biological irradiator using a Cs137 source due to availability and ease of use.

Jig 2.0
The updated jig design was used to perform the high-throughput clonogenic assay on
the H460 cell line exposed to 81.4 MeV protons at MD Anderson’s Proton Therapy Center
(Figure 58). This setup was also used at the HIT facility in DKFZ to expose H460 cells to
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80.6 MeV protons (Figure 59). SF analysis was performed following proton radiation
exposure, fixation and staining, colony scoring. The LQ model was fit to the SF data to
enable comparisons (Table 5, Table 6). The experimental results for the second version of the
high-throughput irradiation apparatus presented similar trends as exposures with the initial
design. Namely, SFs were found to be inversely proportional to exposure with increasing
doses and LETs. The increased sampling of LETs over the experimental range demonstrated
clearer stratification between the results. Irradiation with increasing LET values
systematically resulted in lower SFs for all LETs tested. The results obtained at MDA
between the initial and second generation jig are similar; however, direct comparison
between the two setups is not possible due to different LETs being examined. For the
irradiations performed at HIT, the general trends between the LETs sampled are similar to
those found from proton irradiations at MDA, but the overall radiosensitivity appears to be
lower. The a and b fitting parameters for the experiments performed at MDA also follow the
pattern as before where both increase with the LET. The LQ fitting results from the
experimental run at HIT demonstrated a different trend where a was found to decrease with
increasing LET and b was found to increase with exposure to increasing LET radiation.

Helium
Using the same methodology developed for the high-throughput proton irradiations,
high-throughput measurements of the H460 cell line response to 336.3 MeV helium ions
were performed at the HIT facility in collaboration with the Abdollahi group (Figure 60).
The SFs were found to decrease with increasing dose for a given LET exposure. The SF
reduction rate was found to increase with LET until 52.6 keV/µm. SF reduction then began to
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increase for LETs tested above this value. The LQ model was fit to the clonogenic data with
fitting parameters shown in Table 7. a/ b was found to decrease until 12.2 keV/µm after
which it continually increased. The SF data at the highest LET tested for helium ions, 81.2
keV/µm, was found to consist of only an a component.

Carbon
High-throughput measurements of the H460 response to carbon ions with initial
energy of 1802.5 MeV were performed and data fit to the LQ model (Figure 61, Table 8).
The SFs were found to be lower for exposure with increasing carbon ion LETs. The SFs
found for columns 5, 6, and 7, with LETs of 78.2, 90.4, and 114.7 keV/µm respectively, were
found to be approximately the same. Irradiations with LETs above 114.7 keV/µm were found
to have a decreasing rate of SF reduction. The a/b was found to be approximately constant
for the conditions 114.7 keV/µm, after which it was found to rapidly rise. A pure a
component fit was found for the highest LET tested for carbon ions, 296.4 keV/µm.
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Figure 56. HT clonogenic assay H460 results. H460 SF was found to decrease with
increasing proton LET especially for locations situated near and distal to the Bragg peak
(³11.0 keV/µm). Error bars are SEM.
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Figure 57. HT clonogenic assay H1437 results. Similar to the H460 cell line results, the
H1437 SF was also found to decrease with increasing proton LET especially for locations
situated near and distal to the Bragg peak (³11.0 keV/µm). The H1437 cell line was found to
be overall more radioresistant than the H460 cell line. Error bars are SEM.
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Table 4. H460 and H1437 LQ fitting parameters from Jig 1.0 proton irradiations.
Cell line:

H460

H1437

Column

LET
[keV/µm]

a

b

a SE

b SE

a

b

a SE

b SE

1

1.0

0.267

0.097

0.015

0.007

0.076

0.028

0.049

0.019

2

1.2

0.226

0.111

0.014

0.006

0.135

0.020

0.039

0.013

3

1.6

0.151

0.134

0.013

0.006

0.067

0.027

0.021

0.006

4

1.9

0.149

0.133

0.013

0.006

0.059

0.037

0.020

0.005

5

2.0

0.166

0.134

0.014

0.007

0.094

0.031

0.019

0.005

6

2.5

0.137

0.145

0.016

0.008

0.096

0.032

0.018

0.004

7

3.3

0.205

0.124

0.017

0.008

0.110

0.033

0.022

0.005

8

5.1

0.115

0.153

0.019

0.008

0.034

0.050

0.025

0.006

9

11.0

0.338

0.173

0.024

0.010

0.126

0.062

0.035

0.009

10

14.8

0.498

0.424

0.038

0.025

0.201

0.118

0.048

0.017

11

17.0

0.648

0.782

0.047

0.040

0.357

0.176

0.065

0.031

12

18.3

0.910

1.016

0.056

0.062

0.371

0.289

0.074

0.046

0.290

0.083

0.016

0.004

0.050

0.041

0.012

0.002

Photons
(Cs-137)
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Figure 58. HT clonogenic assay H460 results using second version of the Jig. The second Jig
design demonstrated a deceasing SF following exposure to increasing proton LET. The
increased LET sampling achieved an improved stratification in the observed LET-dependent
separation. Error bars are SEM.

116

Table 5. H460 LQ fitting parameters from Jig 2.0 proton irradiations performed at MDA.
Column

LET
[keV/µm]

a

b

a SE

b SE

1

0.9

0.221

0.102

0.032

0.023

2

2.5

0.276

0.095

0.022

0.009

3

4.1

0.220

0.113

0.025

0.009

4

5.8

0.219

0.122

0.027

0.009

5

6.7

0.192

0.142

0.026

0.009

6

8.5

0.241

0.145

0.029

0.011

7

10.6

0.280

0.196

0.032

0.014

8

12.1

0.295

0.272

0.040

0.021

9

13.5

0.443

0.308

0.044

0.025

10

14.9

0.486

0.424

0.060

0.040

11

16.8

0.753

0.547

0.070

0.055

12

18.0

0.981

0.587

0.077

0.072

0.228

0.103

0.024

0.008

Photons
(Cs-137)
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Figure 59. HT clonogenic assay H460 results from proton irradiations performed at HIT.
The second version of the HT proton Jig was brought to the HIT facility and used to perform
a HT clonogenic experiment. Increased cell kill was found for irradiations with protons of
higher LET. Oddly, the overall radiosensitivity of the H460 to proton radiation appeared to
be increased for the cell line used at HIT. Error bars are SEM.
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Table 6. H460 LQ fitting parameters from Jig 2.0 proton irradiations performed at HIT.
Column

LET
[keV/µm]

a

b

a SE

b SE

1

1.0

0.1686

0.1301

0.04669

0.035

2

2.5

0.0266

0.2069

0.0354

0.01651

3

4.2

0.2447

0.01817

4

6.2

0.2397

0.01617

5

7.5

0.1313

0.2265

0.04995

0.02066

6

9.7

0.06618

0.287

0.04555

0.02252

7

12.2

0.05833

0.3457

0.05304

0.02863

8

13.9

0.09816

0.4353

0.06224

0.03815

9

15.3

0.02242

0.5399

0.06824

0.04531

10

16.8

0.08363

0.6043

0.07933

0.05163

11

18.4

0.02477

0.8317

0.0841

0.06806

12

19.3

0.3071

0.9

0.085

0.08837
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Figure 60. HT clonogenic assay H460 results from helium ion irradiations performed at HIT.
A HT irradiation jig was developed for use with a 336.3 MeV helium ion beam. Clonality was
found to be reduced with increasing helium ion LET until 52.6 keV/µm. For LETs sampled
greater than 52.6 keV/µm, the SFs were found to increase. Error bars are SEM.
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Table 7. H460 LQ fitting parameters from helium ion irradiations performed at HIT.
Column

LET
[keV/µm]

a

b

a SE

b SE

1

3.4

0.3478

0.1235

0.04229

0.02947

2

8.3

0.1575

0.3478

0.04289

0.02685

3

12.2

4

18.8

0.0824

0.533

0.05286

0.03371

5

27.7

0.1682

0.6363

0.09879

0.07514

6

34.7

0.3413

0.7179

0.1067

0.08596

7

44.6

0.7887

0.5532

0.1058

0.08154

8

52.6

0.5314

0.9366

0.1428

0.1279

9

61.5

0.728

0.6872

0.1413

0.1227

10

68.6

0.4933

0.564

0.09448

0.06784

11

74.3

0.5648

0.1526

0.07399

0.04276

12

81.2

0.4548

0.521

0.03335

0.05455
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Figure 61. HT clonogenic assay H460 results from carbon ion irradiations performed at
HIT. A HT irradiation apparatus was designed for use with 1802.5 MeV carbon ions. Similar
to the helium ion results, an inflection point was found for carbon ion irradiations at 90.4
keV/µm. The SFs for cells exposed to carbon ions below this threshold LET were found to
continually decrease. For exposure to LETs above 90.4 keV/µm the SFs were found to grow.
Error bars are SEM.
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Table 8. H460 LQ fitting parameters from carbon ion irradiations performed at HIT.
Column

LET
[keV/µm]

a

b

a SE

b SE

1

20.2

0.4614

0.2661

0.04714

0.03238

2

39.5

0.6798

0.443

0.05285

0.04668

3

61.2

1.256

0.8256

0.1201

0.1331

4

67.3

1.431

0.7269

0.1126

0.1199

5

78.2

1.614

1.104

0.1833

0.2274

6

90.4

1.938

0.8291

0.1465

0.1733

7

114.7

1.738

0.9374

0.1422

0.17

8

142.9

1.923

0.4556

0.141

0.14

9

177.5

1.446

0.4512

0.1038

0.09332

10

224.6

1.221

0.1874

0.07654

0.05326

11

271.4

0.744

0.05245

0.03614

0.01746

12

296.4

0.277

0.02576
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RBEs

Proton
The RBE results for the H460 and H1437 cell lines using the first iteration of the jig
design were calculated by comparison to Cs-137 gamma photon exposed conditions (Figure
62). Both cell lines exhibited similar trends in RBE vs LET response. Overall, the RBE was
found to increase with LET. The portions of the beam proximal to and including the Bragg
peak (columns 1-9; 1-11 keV/µm) exhibited a linear increase in RBE from 1.03 to 1.36 for
the H460 cell line. At positions distal to the Bragg peak (columns 10-12; 14.8-18.3 keV/µm),
the RBE for the H460 cells was found to increase rapidly with LET from 2.09 at 14.8
keV/µm to a maximum value of 3.38 at 18.3 keV/µm.
The RBE trend calculated from the SF results obtained using the second iteration of
the jig for the H460 cell line were found to match the initial results for proton irradiations
performed at MD Anderson (Figure 63). In fact, the increased LET sampling resulted in an
overall smoother trend. More thorough LET sampling in the regions between 5 and 10
keV/µm demonstrated a supralinear trend from the entrance to the Bragg peak region of the
beam. Above the dose peak LET of 10.6 keV/µm, the RBE was again found to rapidly rise.
The largest deviations between the two observed RBE trends were observed at the highest
LETs for each experimental setup with the initial jig design obtaining higher values.
RBEs for proton irradiations performed at HIT were calculated using the published
Cs-137 response values obtained at MDA for the initial Jig experiments. Compiling all the
proton RBE results for the H460 cell line for the two jigs and the two therapy centers results
in similar RBE vs LET trends (Figure 64). Compared to the results obtained at MDA, the
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RBE values found from the experiment at HIT were higher for positions proximal to the peak
dose and lower for the distal portions of the beam. The overall observation of increased RBE
following exposure to protons of increasing LET was consistent between experiments. This
increase was gradual and approximately linear for protons in the plateau region to the Bragg
peak with corresponding LETs between 0.9 keV/µm and 10 keV/µm. For LETs above this
value the RBE was found to rise at an increased rate. The maximum RBE values measured
are within the range of 2.6 and 3.4. Table 9 summarizes the obtained RBE data for all proton
experiments performed.

125

4

H460
H1437

RBE (0.1 SF)

3

2

1
0.5

0

5

10

15

20

LET [keV/µm]
Figure 62. Initial proton RBE results obtained using the first version of the high-throughput
irradiation apparatus. The LET-dependent RBE for both the H460 and H1437 cell lines was
found to be similar. The RBE was found to linearly increase from the entrance to the dose
peak; for LETs in the 1-10 keV/µm range. Above 10 keV/µm, the RBE was found to rapidly
rise. Error bars are SE.
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Figure 63. Proton RBEs obtained from the second Jig version. The H460 RBE was found to
be similar between the initial (Guan et al.) and second version (Jig 2.0) of the HT irradiation
apparatus. The increased LET sampling from 5 to 10 keV/µm demonstrated a supralinear
response for the region proximal to the dose peak (red). For locations distal to the dose peak,
the RBE response was found to rise at an increased rate compared to the proximal region.
Error bars are SE.
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Figure 64. Compiled proton RBE results. The proton RBE results from irradiations at HIT
demonstrated a continual increase with LET (blue). The rate of RBE increase is lower for
LETs associated with the proximal region of the beam (blue, circle). For LETs present in the
distal region of the proton beam the rate of RBE increase was larger. The general trends of
RBE between proton irradiations performed at MDA PTC and HIT were qualitatively
comparable; however, the RBEs found in the range of 1-10 keV/µm were systematically
higher for the HIT dataset than those found in datasets generated at MDA (purple, green).
The RBE trend reversed for LETs above approximately 10 keV/µm where the HIT dataset
demonstrates persistently lower RBEs than the MDA datasets. Error bars are SE.
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Table 9. Compiled proton RBE values.
H460
Column

Jig 1.0

H1437

Jig 2.0 MDA

Jig 2.0 HIT

Jig 1.0

LET
[keV/µm]

RBE

LET
[keV/µm]

RBE

LET
[keV/µm]

RBE

LET
RBE
[keV/µm]

1

1.0

1.03

0.9

0.99

1.0

1.05

1.0

0.88

2

1.2

1.04

2.5

1.02

2.5

1.16

1.2

0.88

3

1.6

1.05

4.1

1.03

4.2

1.24

1.6

0.85

4

1.9

1.04

5.8

1.06

6.2

1.22

1.9

0.98

5

2.0

1.06

6.7

1.10

7.5

1.30

2.0

0.95

6

2.5

1.07

8.5

1.15

9.7

1.40

2.5

0.97

7

3.3

1.06

10.6

1.34

12.2

1.52

3.3

1.01

8

5.1

1.08

12.1

1.55

13.9

1.73

5.1

1.08

9

11.0

1.36

13.5

1.78

15.3

1.86

11.0

1.34

10

14.8

2.09

14.9

2.05

16.8

2.01

14.8

1.90

11

17.0

2.81

16.8

2.54

18.4

2.30

17.0

2.53

12

18.3

3.38

18.0

2.85

19.3

2.64

18.3

3.08
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Helium and carbon ions
Calculating RBEs for the helium and carbon ion experiments performed at the HIT
facility using the previously measured response of H460 cells to Cs-137 photons resulted in
unique RBE trends compared to the proton irradiations (Figure 65, Table 10). The helium
RBE was found to continually increase from the initial value of 1.21 for exposure to helium
ions with an LET of 3.4 keV/µm present at the beam entrance to a maximum value of 2.90 at
52.6 keV/µm. For LETs sampled above 52.6 keV/µm, the RBE was found to rapidly
decrease to a minimum value of 0.75 at 81.2 keV/µm.
The carbon ion RBE followed a similar pattern as helium ions. The entrance RBE
was measured to be 1.72 at 20.2 keV/µm. The RBE increased with carbon ion LET until a
maximum value of 4.38 for carbon ions with an LET of 90.4 keV/µm. Above this LET, the
RBEs were found to decrease until the lowest value measured of 0.46 at the highest LET
sampled, 296.4 keV/µm.
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Figure 65. Proton, helium and carbon ion RBE results from HIT irradiations. The helium
and carbon ion datasets demonstrated an increase in RBE until an ion-specific LET value at
which point the RBEs were found to reduce from the maximum. This feature was not present
in the proton RBE. Error bars are SE.
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Table 10. Heavy ion RBE values.
Column

Helium

Carbon

LET
[keV/µm]

RBE

LET
[keV/µm]

RBE

1

3.4

1.21

20.2

1.72

2

8.3

1.61

39.5

2.32

3

12.2

1.80

61.2

3.53

4

18.8

1.89

67.3

3.61

5

27.7

2.14

78.2

4.27

6

34.7

2.42

90.4

4.38

7

44.6

2.62

114.7

4.24

8

52.6

2.90

142.9

3.90

9

61.5

2.76

177.5

3.25

10

68.6

2.33

224.6

2.48

11

74.3

1.55

271.4

1.45

12

81.2

0.75

296.4

0.46
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High-throughput immunofluorescent results

Protons at MD Anderson Proton Therapy Center
The second version of the irradiation apparatus was used to performed highthroughput DNA damage repair kinetic studies. Cells were seeded on glass bottom plates and
subjected to a single dose of protons. Following irradiation, the plates were returned to
culture for repair to occur. Plates were fixed over a time course of 24-30 hours following
irradiation for subsequent immunofluorescent DSB foci staining. Plates were imaged on an
automated microscope at 20x magnification with 16 images per well obtained. The images
were analyzed with the CellProfiler software package to measure the foci within each
nucleus.
For all dose-LETs sampled, the results of the foci scoring analysis demonstrate the
greatest number of foci at the initial fixation time point at 30 minutes post-irradiation
followed by a reduction until the terminal assay time point (Figure 66). For proton
irradiations, the DSB repair kinetics were modeled by a standard exponential decay function
(Figure 67). The foci repair half times were found to increase with increasing proton LET.
To determine the dose dependence of DSB induction and persistence following
proton exposure, cells were irradiated to dose levels corresponding to peak doses of 0.96,
1.92, and 3.44 Gy using the second iteration of the jig. The number of foci at 30 minutes
following irradiation was found to increase from the 0.96 and 1.92 Gy peak dose exposures;
however, a saturation in early foci was found for exposures associated with the 3.44 Gy peak
dose for LETs above 2.59 keV/µm (Figure 68). A linear response between dose and the
number of persistent foci, was observed (Figure 69).
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Figure 66. Representative DSB repair kinetics. H460 cells were exposed to a peak dose of
1.92 Gy and returned to culture for fixed periods of time before fixation and
immunofluorescent labeling the DSB repair protein 53bp1. Error bars represent 95%
confidence intervals.
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Figure 67. Normalized DSB repair kinetics with fit. Data was analyzed by subtracting the
background and normalizing to the initial value of induced foci at 30 minutes. Error bars
represent 95% confidence intervals.
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Figure 68. Induction foci vs dose and LET. H460 cells were exposed to 3 different dose levels
using the HT irradiation setup. The number of induced DSBs was set as the number of foci at
30 minutes post-irradiation. The number of initial foci detected demonstrated a saturation
for conditions at the highest dose levels for LETs above 2.59 keV/µm. Error bars represent
95% confidence intervals.
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Figure 69. Persistent foci vs dose and LET. Persistent foci were defined as DSB foci above
background present at the terminal fixation time point in an experiment. The amount of
persistent foci was found to increase with exposure to increasing proton LET regardless of
delivered dose with the exception of the lowest LET tested. The number of persistent foci for
a given LET condition was found to be linearly proportional to the dose delivered (lines).
Error bars represent 95% confidence intervals.
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A linear quadratic model was used to compare the number of persistent DSBs for a
given dose-LET combination with the corresponding surviving fraction determined from the
high-throughput clonogenic assays (Figure 58) (Figure 70). The correlation between the
number of persistent DSBs and SF indicated that there was a relationship between the
mechanistic DSB and the functional biological response of colony formation. When
normalized for dose, the number of induced foci was found to be similar for the LET
extremes sampled (Figure 71). The induction trend decreased from LETs of 0.97 keV/µm to
10.92 keV/µm where the minimum number of foci were found. The number of induced foci
at 30 mins following irradiation then increased above 10.92 keV/µm to the maximum value
at 18.75 keV/µm. The dose-normalized persistent foci were found to be consistent from 2.59
keV/µm to 6.84 keV/µm whereas the 0.97 keV/µm condition exhibited a higher value than
those present in this range. For the LETs sampled above 6.84 keV/µm, in the range in 8.68
keV/µm and 18.75 keV/µm, the number of persistent foci per Gy was found to rapidly rise
(Figure 71).
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Figure 70. Correlation between persistent DSBs and SF. A linear quadratic correlation was
found between the number of persistent foci present and the respective SF resulting from the
corresponding dose-LET combination.
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Figure 71. Induced and persistent DSBs vs LET for protons. Dose normalizing the number of
induced and persistent foci demonstrated the energy-normalized DSB induction (blue) and
persistence (red) efficiency for each proton LET. The relationship between dose-normalized
persistent DSB foci and LET appeared analogous to those observed for RBE vs LET. Error
bars represent 95% confidence intervals.
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Helium and carbon ion irradiations performed at HIT
The immunofluorescent DSB foci repair assay was performed for H460 cells
irradiated by helium or carbon ions at HIT. The peak dose the cells were exposed to was 3.13
Gy for helium ions and 2.80 Gy for carbon ions. The repair kinetics for cells exposed to
helium ions were appropriately fit to an exponential decay equation (Figure 72). The repair
time course for cells exposed to carbon ions was fit by an exponential decay equation for the
LETs sampled between 20.1 keV/µm and 134.1 keV/µm as well for 301.5 keV/µm, the
highest LET sampled. The LETs of 170.5, 224.1, and 271.4 keV/µm were unable to be
modeled by a simple exponential model due to a shared trend between these conditions
where an initial reduction in the number of foci was observed up to approximately 4 hours
post-irradiation. DNA repair was then followed by an increase in the number of foci from the
4 hour time point in the 8 and 12 hour time points followed by a reduction at the terminal
time point assayed (Figure 73). Similar repair trends where the 8 or 12 hour time points
exhibited an increased foci signal compared to the previous time points were observed in the
LETs between 60.0 and 134.5 keV/µm, but these LET conditions were able to be fit to an
exponential reduction model.
The dose-normalized induction foci for the helium and carbon ions were found to
decrease with increasing LETs (Figure 74). For helium ions, the number of dose-normalized
persistent foci was found to increase with LET until a maximum at 57.6 keV/µm. For higher
LETs above 57.6 keV/µm, the number of persistent foci was found to consistently decrease
(Figure 75). A similar trend in the number of persistent foci versus LET for carbon ions was
observed. For irradiation with carbon ions, the number of persistent foci was found to
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increase from 20.1 to 86.5 keV/µm. The trend was then reversed for LETs above 86.5
keV/µm (Figure 75).
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Figure 72. Helium ion DSB repair kinetics. H460 cells were irradiated to a peak dose of 3.13
Gy with a 336.3 MeV helium ion beam at the HIT facility. DSB repair was measured via
53bp1 foci staining. Data points were fit with to a one phase decay equation. Error bars
represent 95% confidence intervals.
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Figure 73. Temporal DSB repair following exposure to carbon ions. 53bp1 foci staining was
performed on H460 cells following a peak dose exposure of 2.80 Gy from an 1802.5 MeV
carbon ion beam. A single phase decay model was fit to the results. Fitting did not converge
for the 170.5, 224.1 and 271.6 keV/µm conditions. Error bars represent 95% confidence
intervals.
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Figure 74. Dose-normalized induced foci at 30 mins post-irradiation for proton, helium, and
carbon ion beams. With increasing particle LET, the helium and carbon ions exhibited
consistent downward trends within the number of induced foci per Gy. The proton beam
followed a downward trend with increasing LET until the peak dose LET after which the foci
induction efficacy was found to increase with LET. Error bars represent 95% confidence
intervals.
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Figure 75. Dose-normalized persistent foci for proton, helium, and carbon ion beams. The
dose-normalized persistent foci trends correspond with the RBEs at 0.1 SF. Error bars
represent 95% confidence intervals.
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GSC high-throughput results

Growth curves
To test the effect of proton radiation quality in an additional in vitro system
glioblastoma stem cell (GSC) lines were chosen as a unique model of interest. GSCs are
patient derived cell lines that grow as a spheroidal suspension. GS7-11, GSC300, or GSC23
single spheroids per well were formed using ultra-low attachment round bottom plates. The
spheroids were exposed to proton radiation in the initial version of the high-throughput
irradiation system with subsequent spheroid size measurements over a time course of
approximately 30 days. The size measurements demonstrated an LET dependent increase in
spheroid growth delay with increasing dose (Figure 76). Alternatively, the biological
response mapping demonstrated that preventing spheroid regrowth required lower doses for
high-LET (Figure 77). The spheroids were found to exponentially grow for smaller volumes
(Figure 78). The spheroid growth was found to linearize for larger spheroid sizes, likely a
result of hypoxia occurring at the core. The maximum spheroidal diameter typically achieved
in control and low biological damage conditions was between 1.0 and 1.3 mm.
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Figure 76. Representative GSC size measurements following irradiation with protons with
the HT system. The growth response of GS 7-11spheroids following irradiation with LETs of
3.0 and 16 keV/µm. Both conditions receive approximately the same dose per irradiation
which was near half the peak dose. The spheroids subjected to the 16 keV/µm protons were
found to have a larger growth delay as well as no growth at doses above 2.8 Gy. Complete
growth prevention was not achieved even at a dose of 6.4 Gy for the 3.0 keV/µm condition.
Error bars represent 95% confidence intervals.
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Figure 77. 4D representation of GSC23 response. The surface plots demonstrate the
technical changes faced when analyzing mapped biological responses with additional
physical parameters. Peak doses in column 9 of (A) 2.75 Gy, (B) 5.50 Gy, (C) 8.24 Gy, (D)
10.99 Gy, and (E) 17.35 Gy were delivered to GSC23 spheroids using the initial jig design.
The biological response was observed at lower doses for high LET protons. With increasing
dose, the growth was prevented for both low and high LETs indicating the LOD of the assay
had been reached. Plots were generated using mathplot.lib in the Python coding language
with the assistance of Landon Wootton, PhD.
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Figure 78. Growth constant calculations. Normalized GSC spheroid growth were fitted with
a general exponential growth equation. Error bars are standard deviations (SD).
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Surviving fractions
Using the size measurements of control and irradiated spheroids, the resulting SFs
were calculated by determining the cell line specific growth constant and the growth delay
between the experimental and control conditions (99). For all GSC lines tested, irradiation
with increasing LET was found to result in reduced clonogenic survival (Figure 79-Figure
81). The GSC SF data was fit to the LQ model (Table 11, Table 12). In general, column 8
(4.7 keV/µm) exhibited increased survival compared to other conditions.

RBEs
Using the LQ model fits to the SF data, RBEs at 0.1 SF were calculated for the GSC
cell lines tested (Figure 82). As previously observed, the proton RBE was found to rapidly
rise beyond the Bragg peak value of 10.2 keV/µm. The RBEs for the GSC23 cell line were
calculated with a control radiation of 6MV x-rays whereas the reference source for GS7-11
and GSC300 was Cs-137. An additional RBE of 1.07 for Cs-137 was applied to the GSC data
to normalize the results for comparison (Figure 83). The GSC RBEs for LETs less than 10
keV/µm were approximately 0.9-1.1. The RBEs for the distal portions of the proton beam
(i.e. LET > 10 keV/µm) were found to be in the range of 2-6.
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Figure 79. GS7-11 SFs. The SFs for the GS7-11 GSC line irradiated in the initial version of
the HT irradiation setup were found to follow a similar trend as observed for the H460 and
H1437 cell lines. SF was found to decrease with increasing doses. Cell kill was enhanced for
proton LETs beyond the peak dose value of 10.2 keV/µm. Error bars are SD.
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Figure 80. GSC300 SFs. SF reduction was increased by exposure to protons of increasing
LETs. The GSC300 cell line was found to have a higher intrinsic radioresistance than the
GS7-11 line as evident by the increased dose required to induce the same SF. Error bars are
SD.
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Table 11. GS7-11 and GSC300 LQ fitting parameters.
Cell line:

GS7-11

GSC300

LET
[keV/µm]

a

b

a SE

b SE

a

b

a SE

b SE

2.3

0.169

0.075

0.018

0.005

0.085

0.075

0.023

0.006

3.0

0.183

0.067

0.022

0.006

0.076

0.072

0.022

0.006

4.7

0.179

0.054

0.026

0.006

0.058

0.066

0.017

0.004

10.2

0.254

0.045

0.019

0.005

0.116

0.064

0.023

0.005

14.1

0.504

0.130

0.041

0.018

0.253

0.168

0.043

0.016

16.0

0.856

0.431

0.115

0.086

0.365

0.612

0.040

0.028

17.1

1.943

1.089

0.178

0.227

0.565

1.311

0.166

0.174

Photons
(Cs-137)

0.226

0.048

0.015

0.005

0.119

0.056

0.020

0.004
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Figure 81. GSC23 SFs. SFs for the GSC23 cell line were obtained using the initial version of
the HT irradiation apparatus and spheroid growth delay measurements. The SF was found to
be significantly lower following high LET proton exposure. Error bars are SD.
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Table 12. GSC23 LQ fitting parameters.
Cell line:
LET
[keV/µm]

GSC23

a

b

a SE

b SE

2.3

0.066

0.003

3.0

0.068

0.003

4.7

0.056

0.003

10.2

0.065

0.004

14.1

0.000

0.188

0.042

0.009

16.0

0.000

0.606

0.079

0.057

17.1

0.123

1.510

0.091

0.063

Photons
(6MV)

0.000

0.070

0.017

0.004
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Figure 82. GSC RBEs. RBEs were calculated for the GSCs by taking the ratio of the dose of
the respective photon control radiation to achieve an SF of 0.1 to the dose require for the
assayed proton LETs to achieve the same response. The RBE for all GSCs used was found to
be approximately 1 for LETs less than 10.2 keV/µm. The RBE was found to systematically
rise for all LETs above this value. Error bars are SE.
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Table 13. Compiled GSC RBE values.
LET
[keV/µm]

RBE
GS7-11

GSC300

GSC23

2.3

1.08

1.06

0.97

3.0

1.07

1.05

0.99

4.7

0.97

0.98

0.89

10.2

1.03

1.05

0.96

14.1

1.84

1.77

1.64

16.0

3.26

3.21

2.95

17.1

6.11

4.75

4.81
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Figure 83. GSC RBEs with applied photon RBE. The control radiation for the GSC23
experiments was 6 MV photons; however, the control radiation for the GS7-11 and GSC300
cell lines was gamma rays from Cs-137. The calculated RBEs were adjusted assuming an
RBE of Cs-137 of 1.07. Error bars are SE.
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Rat brain microtissue response to proton irradiation

Size
Rat brain microtissues (RBMTs) were exposed to radiation of different qualities and
followed by a longitudinal study of the size response. Control radiation was photons
produced from the decay of Cs-137. Test radiations were protons with LETs of 3, 10, or 16
keV/µm. LET sampling was achieved using columns 7, 9, and 11 of the initial version of the
high-throughput irradiation setup. Whole plates of RBMTs were not used due to the
longitudinal nature of late effect studies for multiple conditions and the cost associated with
the microtissues. The chosen LET conditions represent a broad range of proton LET as well
as convenience of comparison as columns 7 and 11 receive half the dose of the peak dose in
column 9 for each irradiation.
The size response of RBMTs exposed to the four irradiation conditions was followed
for a period of 76 days (Figure 84-Figure 87). Non-irradiated RBMTs grew by a factor of 1.3
- 1.5 before stabilizing and maintaining their size for the remaining duration of the time
course. Irradiated spheroids were found to stratify in a dose and LET dependent manner. Size
reduction was found to correspond to exposure with higher doses resulting in larger
decreases in size. After 40-50 days, a lower bound of approximately half the original
spheroid size was seen in the size response as RBMTs receiving the largest doses did not go
below this threshold for any of the tested irradiation conditions.
Comparing the size response of the four exposure conditions at 50 days postirradiation demonstrated the decreasing size of the spheroids towards the lower bound of the
response (Figure 88). The response characteristics were similar for the photon, low (3
keV/µm), and intermediate (10 keV/µm) proton LET conditions. The high LET condition (16
160

keV/µm) approached the lower threshold size for much lower doses than the other
conditions.
The size data at day 50 was fit to a four-parameter sigmoid model by non-linear
regression with GraphPad Prism 7.0 (Figure 89). 50% response doses (D50s) were calculated
from the fits and normalized to the Cs-137 response to determine the RBE of the different
proton LETs (Figure 90). The RBE values were found to be 1.2, 1.4, and 5.9 for proton LETs
of 3, 10, and 16 keV/µm respectively.

Viability
Late term RBMT viability was assayed 55 days following irradiation using the
RealTime-Glo MT Cell Viability Assay (Figure 91). Above 2 Gy, the viability signal of the
photon, 3 keV/µm, and 10 keV/µm protons was found to be similar. The RBMTs exposed to
16 keV/µm protons had a significantly lower viability signal and reached a lower threshold
value for lower doses than the other experimental conditions. Surprisingly, the viability trend
was found to reverse between the 3 and 16 keV/µm conditions for the low doses tested near
1Gy. The raw viability data was fit to the four-parameter sigmoid model by non-linear
regression with GraphPad Prism 7.0 to enable RBE determination (Figure 92). The RBEs for
the proton conditions to achieve a 50% reduction in viability signal vs the Cs-137 condition
were found to be 1.04 for 3 keV/µm, 1.07 for 10 keV/µm, and 3.65 for 16 keV/µm (Figure
93).
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Figure 84. RBMT size response following exposure to photons produced by Cs-137.
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Figure 85. RBMT size response following exposure to 3 keV/µm protons.
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Figure 86. RBMT size response following exposure to 10 keV/µm protons.
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Figure 87. RBMT size response following exposure to 16 keV/µm protons.
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Figure 88. RBMT size comparison at 50 days post-irradiation. Size reduction was found for
all RBMTs subjected to any form of radiation. The reduction was dose dependent. The Cs137, 3 keV/µm, and 10 keV/µm conditions all demonstrated similar size reductions with dose
and an overall linear reduction trend from 0 to 20 Gy. The reduction for the Cs-137 and 10
keV/µm from 20 Gy to 40 Gy demonstrated a reduced response rate towards the minimum
size achievable. In comparison, the 16 keV/µm exposed RBMTs exhibited a relatively rapid
size reduction achieving the minimum size at approximately 5 Gy.
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Figure 89. Fit to day 50 RBMT size data. The RBMT size data was fit to a four-parameter
sigmoidal response model by non-linear regression to enable the comparison between the
radiations by the calculation of the doses to achieve a 50% response (D50).
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Figure 90. RBE at 50% of RBMT size. D50s were calculated for the terminal RBMT size
response following exposure to Cs-137 photons, 3, 10, or 16 keV/µm protons. The calculated
D50s were normalized to the value obtained for the Cs-137 condition to determine the RBE
at 0.5 response. The observed trend was analogous to the RBE vs LET trends seen for the
other model systems where the RBE gradually increased for LETs present in the proximal
region of the beam (<10 keV/µm) and then rapidly increased for the distal portion of the
beam. The errors present are SE.
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Figure 91. Viability of RBMTs following exposure to photons and protons with LETs of 3, 10,
or 16 keV/µm. RBMT viability was assayed using the Realtime-Glo MT cell viability assay.
The general viability trends were similar to those found by size measurements. The highest
LET sampled, 16 keV/µm, was found to have an initial rise for a dose of 1 Gy followed by a
drastic reduction to the minimum viability achieved. The other conditions tested were found
to have similar responses with the exception of the 3 keV/µm condition irradiated to 1 Gy.
This condition demonstrated a reduced viability signal at 1Gy. For other doses tested, this
condition was found to have similar values as the 10 keV/µm and Cs-137 irradiated RBMTs.
The 3 and 10 keV/µm as well as Cs-137 irradiated RBMTs demonstrated an increased
viability signal until 5Gy. At doses higher than 5 Gy, the viability signal was found to
decrease to the minimum value at 20 Gy.
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Figure 92. Response fit to RBMT viability data. The RBMT viability data was fit to a fourparameter sigmoidal response model by non-linear regression for calculation of the D50.
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Figure 93. RBE at 50% viability for RBMTs. Using the fits to the viability data, RBEs at 50%
response were calculated compared to the response achieve from the Cs-137 group. A large
increase in RBE was present for the RBMTs exposed to the 16 keV/µm protons. A modest
RBE increase was demonstrated for RBMTs exposed to the 3 and 10 keV/µm protons. Errors
are SE.
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RBMT composition after radiation
Immunofluorescent staining
The bulk composition of RBMT spheroids 80 days post-irradiation was visualized
with immunofluorescent staining of neurons and glia using the markers of beta-III tubulin
and glial GFAP respectively (Figure 94-Figure 100).
The images for the RBMTs exposed to high LET protons demonstrated that for the
lowest dose of 0.9 Gy, there was an increased expression of beta-III tubulin compared to the
unirradiated control tissues. This effect was also present in one of the replicates for the 2.25
Gy exposure; however, the other replicate demonstrated a significantly lower expression. An
increase in the beta-III tubulin expression was also observed for the low and intermediate
LET protons at higher doses (2.75 - 5.35Gy) than for the 16 keV/µm protons but not in the
Cs-137 irradiated replicates. For doses above 2.25 Gy for the 16 keV/µm protons and 5 Gy
for the 3 and 10 keV/µm protons, the beta-III tubulin expression declined. The beta-III
tubulin expression was found to continually decrease above 2 Gy for the photon condition.
The beta-III tubulin expression appeared to be the same for all conditions as doses
approached 20 Gy.
The GFAP expression was observed to generally decrease with increasing doses for
all the tested radiation qualities compared to the non-irradiated control tissues. Exposure to
increasing 16 keV/µm protons reduced the GFAP expression at a much faster rate than for
the other conditions. The other irradiation conditions did not appear to achieve the low GFAP
expression values reached by the 16 keV/µm protons.
Image analysis was performed by calculating the integrated pixel intensities of the
images by thresholding the images using Fiji. This semi-quantitative analysis confirmed the
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results achieved by manual inspection (Figure 101, Figure 102). However, this analysis
found that the GFAP expression for the RBMTs exposed to 10 Gy of Cs-137 photons or 10
keV/µm protons increased from previous dose level of 5 Gy before further reduction.
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Figure 94. Immunofluorescent staining of unirradiated control RBMTs at 80 days.

174

Figure 95. Immunofluorescent staining of RBMTs at 80 days following exposure to 1Gy.
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Figure 96. Immunofluorescent staining of RBMTs at 80 days following exposure to 2Gy.
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Figure 97. Immunofluorescent staining of RBMTs at 80 days following exposure to 5Gy.
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Figure 98. Immunofluorescent staining of RBMTs at 80 days following exposure to 10Gy.
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Figure 99. Immunofluorescent staining of RBMTs at 80 days following exposure to 20Gy.
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Figure 100. Immunofluorescent staining of RBMTs at 80 days following exposure to 40Gy.
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Figure 101. Quantification of beta III tubulin expression. Semi-quantitative analysis of the
RBMT b-III tubulin expression indicated that the response is related to the viability results
observed.
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Figure 102. Quantification of GFAP expression. Preliminary results indicated a reduction in
GFAP expression with increasing dose. Additionally, a reduction in GFAP expression
achieved by the 16 keV/µm was found.
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Discussion
This work establishes the methodology to design and apply generalized screening
techniques with the purpose of achieving a dramatic increase in the quantity and quality of
data acquired from charged particle beam irradiation experiments. This dissertation presents
the results obtained using the developed high-throughput (HT) irradiation apparatus in three
biological effect model systems. In each of the model biological systems utilized, all
endpoint results demonstrated a non-linear trend in RBE and proton LET. Although recent
studies have indicated that RBE and LET scale linearly, our results suggest that the
relationship between LET and biologic effect may not be so straightforward and suggests the
need to account for such effects proactively in the treatment planning process (9, 101, 102).
The overall goal of this work was to increase the quality and speed of obtaining
particle beam radiobiological data. To the author’s knowledge, no other studies have
demonstrated a comprehensive method of applying high-throughput techniques to map the
biological effect of charged particle radiation. However, when developing an iterative
improvement on established methods, it is imperative to place the results in the proper
comparative context. In this regard, other groups have performed similar rigorous studies
using the lower-throughput, traditional methods to assay biological effects along charged
particle beams (16, 101-103). Furthermore, these studies have been indexed in
comprehensive reviews and databases such as the particle irradiation data ensemble (PIDE)
(5).
Before placing our results in the context of the literature, it should be noted that the
experimental results obtained for the H460 cell line with exposure to photons of differing
energy spectra demonstrate that the selection of control radiation can have a significant
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impact on the overall reported results. Additionally, the biological endpoint selected for SF
and RBE calculation can affect the results (49). RBEs for particle radiations presented have
been calculated at 0.1 SF compared to Cs-137 photon irradiation. The selection of Cs-137 as
the control radiation for this work was due to convenience. Experimental irradiations
typically took place from late night to early mornings or over the weekends (or both). As
such, access to a clinically used linear accelerator was limited compared to the preclinical
biological irradiator. RBEs at 0.1 were calculated in correspondence with the most common
value observed in the relevant literature.
For the H460 and H1437 adherent cell lines exposed to proton radiation, the
measured RBEs in the distal falloff region of the beam are considerably higher than those
typically reported in the literature as well as the clinically used value of 1.1. However, as
previously mentioned there is a large spread in proton RBE results in the literature. As such,
the RBE values obtained with the HT system fall within the range of the spectrum of values
that have been reported (8, 9, 104). Similar RBE values to our data were observed by
Chaudhary et al. in the human cell lines AG01522 and U87, derived from fibroblasts and
glioblastoma, respectively (101). Similar to the presented results, the relationship between
RBE and LET in this work appears supralinear. This trend was especially evident for the
human glioblastoma U87 cell line at RBEs calculated for a 0.5 SF.
The general trend measured between RBE and LET and absolute values for helium
and carbon ions are similar to the literature values compiled within the PIDE 2.0 database
(5). In both helium and carbon irradiations, the overkill effect, a reduction in biological
effectiveness at high LET, was noted to occur for the highest LETs tested for each particle,
an effect not observed in any of the proton experiments. For helium ion irradiations
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performed at HIT with the HT system, the maximum RBE was measured at 52.6 keV/µm.
This result is significantly lower than published literature values. Tracy et al. measured as
well as compiled published RBE(0.1 SF) for mammalian cells exposed to He ions (105).
Within their work, they measured a maximum RBE at 131 keV/µm in V79-4 cells. Folkard et
al. found a maximum RBE at 88.3 keV/µm for V79 cells (106). Furusawa et al. did not
achieve overkill with He ions in V79 or HSG cells for maximum LETs tested of 90.8 and
71.0 keV/µm respectively (107).
For carbon ions, the maximum RBE was measured at an LET of 90.4 keV/µm. This
value is also lower than measured by previous studies. Weyrather et al. measured a maximum
RBE in CHO and V79 cells at 153.5 keV/µm (108). For V79 and HSG cells Furusawa et al.
measured the maximum carbon ion at 137 keV/µm. For T1 cells the maximum RBE
inflection point was measured at 109 keV/µm (107).
The lack of overkill effect for the highest proton LETs measured in the HT
irradiations is not unexpected as the overkill effect for protons is expected to occur for LETs
greater than 20 keV/µm. The literature examining the exposure of cells to proton LETs above
the 20-23 keV/µm range is limited. Published results with proton LETs higher than this range
utilized a Van de Graff generator to produce low energy protons. Belli et al. reported a
maximum proton RBE(0.1 SF) for 30.5 keV/µm protons in V79 cells (109). Overkill was
observed for the higher LETs tested, 34.6 and 37.8 keV/µm. Folkard et al. exposed V79 cells
to proton radiation with LETs of 10.1,17.8, and 27.6 keV/µm (106). Consistent with the Belli
results, the overkill effect was not observed as the corresponding RBEs were measured to be
1.25, 1.40, and 1.91.
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Determining the underlying mechanisms behind the observed differences between the
presented RBE vs LET results, particularly for the higher LETs present within a given
particle type, is a complex task. A possible explanation for the observed differences between
the literature and the presented RBE vs LET results could be variations in the experimental
setups utilized. Much of the data available for high LET interactions within the literature
were measured with either non-clinical Van de Graff generators or cyclotrons which produce
beams with very narrow energy spectra. Other data points have been measured with clinical
setups utilizing SOBPs which serves to broaden the energy spectra at a given location within
a beam. The current work utilizes a system that falls in the middle of these two experimental
setups. An additional confounding factor is the simulation parameter setups used to calculate
dose and LETs between the numerous groups studying charged particle RBE. It has been
shown that even in the simplest geometry of a homogeneous water medium that different MC
packages will calculate different dose and LETs (110).
LET effects aside, an additional consideration for RBE comparison is inherent
sensitivity to particle radiation. While there are many data points for the various charged
particles under study for use in cancer treatments, many studies have used either non-human
or non-cancer derived cell lines. While the DDR is highly conserved pathway between
species, the mutations carried by cancer cells result in an increased amount of variation in the
response space. Using a panel of 17 NSCLC cell lines, Liu et al. recently displayed a large
spread of RBEs measured at the mid-SOBP of a clinical proton beam (111). Cancer cell lines
derived from human cells, the same type of cancer, and irradiated under the same conditions
exhibited strikingly different RBEs.
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The high-throughput clonogenic methodology is subject to the inherent as well as
unique constraints compared with traditional clonogenic assay techniques. For the general
clonogenic assays methods, we attempted to remove and minimize possible artifacts. Semiautomated, pre-plating was used to quickly seed all cells from a single stock solution within
10-15 minutes. The use of a single seeding solution per experiment results in a single
multiplicity correction (42, 43). A single stock solution also reduces the number of counting
uncertainties present within a given clonogenic experiment to the minimum value of one.
Complicating biological processes from cellular manipulation were minimized from the
readout of colony formation by pre-plating the cells.
The largest difference to consider when performing the clonogenic assay in a 96-well
microplate is the well growth area of a standard 96-well plates is considerably smaller than a
6-well plate, petri dish, or flask. This reduced area effectively limits the number of cells that
can be seeded for colony formation in a cell line specific colony morphology-dependent
manner. Only cell lines that form distinct colonies can effectively utilize the limited growth
area. The maximum number of cells that can be seeded without substantial colony overlap in
high-SF plates is limited to approximately 200 (112). The seeding density limitation restricts
the range of measureable SFs, making achievable doses cell line-dependent. This obstacle
may be possible to circumvent for some cell lines by altering the seeding density within each
well based on the expected cell kill as is done in the traditional clonogenic assay (113). Our
attempts to increase the seeding density beyond 250 cells per well for the H460 and H1437
lines resulted in a population of quiescent cells that were found to limit and obscure colony
growth. Additionally, we desired to avoid any cell seeding density effects on the results and
as such utilized a constant seeding density.
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Throughout the course of this body of work, it has become evident that
immunofluorescent techniques and the HT system are well suited for use together. The
relationship between the HT measured RBE at 0.1 SF and the number of persistent DSB
induced per Gy are well correlated indicative of the casual nature of the relationship. Many
of the issues present for the HT clonogenic are not problematic with the use of
immunofluorescent assays. Rather, with immunofluorescence assays, the largest obstacle
(aside from the increased material cost) is the increase in the amount of data generated per
irradiation. Analysis of considerably large image datasets requires automated analysis
software. The initial setup and benchmarking of automated software is time consuming.
However, once developed, the analysis recipe can be easily shared, and if robust, applied to
additional experiments (114-116). Images with artifacts effecting automated scoring need to
be reduced and removed from the overall tallied results. As the number of conditions
increases, the time spent manually verifying results becomes unreasonable. Improvements in
machine learning algorithms are already reducing the time needed for automatic scoring
implementation with a higher accuracy than previous static iterations. Additional applications
of immunofluorescent labeling techniques may also be useful in future experiments to
determine persistent foci for time points later than 24-30 hours post-irradiation. It has
recently been shown that the relative change in the number of DAPI- stained nuclei in such
studies correlates well to SF (117). This approach coupled with the high-throughput
irradiation method could be used to simultaneously perform mechanistic studies and
determine RBE. Furthermore, the combination of these methodologies would eliminate
susceptibility to the colony size limitation present with the HT clonogenic assay enabling the
use of cell lines previously unsuitable for the HT clonogenic assay.
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There is evidence in the literature indicating differential DSB repair pathway
utilization following irradiation with protons or carbon ions. However, contradictory findings
in relation to the effects of irradiation with increased LET on the DSB repair pathway have
been reported (118, 119). In future HT mechanistic studies, markers downstream of the initial
damage response may be utilized to differentiate between the DNA repair pathways to
validate and further elucidate the LET-dependence for the formation of persist foci. Markers
of particular interest would be DNA-PKcs for NHEJ and Rad51 for HR.
The current application of spheroidal cancer cell line cultures utilizes the HT
irradiation methodology at the expense of multiple colonies per well. However, this method
demonstrates an increase in throughput when compared to previous studies where GSC
clonogenicity was measured using single cell per well dilutions. The size distributions
measured within each experimental condition showed little variation between replicates.
Our work utilizing rat brain microtissues is unique in that the toxicities in normal
tissues following radiation have been understudied because methods to do so are limited. In
terms of late effects associated with brain irradiation, cognitive impairment receives the most
attention (120). Furthermore, there are very few studies examining normal brain tissue
response following exposure to charged particle radiation. Studies demonstrating the
response of photon radiation on neuronal cultures are more numerous, and there are a few
sources in the literature for particle beams (121, 122). These studies do not account for the
presence of additional cell types making up the neuronal microenvironment and the
subsequent interactions following radiation insult. In the context of more advanced ex vivo
studies, organotypic slice cultures have been used to study the normal brain response (123,
124). General results with these models are in agreement with the findings reported in this

189

work. However, additional studies will need to be performed to determine the induction and
progression of radiation therapy toxicities such as necrosis.
For the proton RBE studies involving size based measurements, the RBEs for LETs
>10 keV/µm in GSC and RBMTs are higher than those found when using adherent or other
biological endpoints. This is an unexpected finding as LET effects are expected to diminish
over larger target volumes. The concept of LET is problematic for spheroids because their
geometry is not conducive to the calculation of particles crossing two parallel surfaces.
While our work demonstrates high reproducibility between repeated experiments
under the same conditions, the effect of the MC simulations on the dose and LET
calculations needs to be carefully considered. The simulation ultimately affects the
experimental results found by altering the independent axis of the experiments. Within this
work, there was a difference noted between the HT proton irradiations performed at MDA
and HIT. This feature is the result of the differences in MC implementation between the
experiments. When the MC simulations utilize the same setup parameters, the results and
trends are found to be a significantly closer match. Thus, the dose and LET calculations
derived from the MC simulations are potentially problematic due to limited knowledge of the
physical description of particle interactions, especially at low energies and for materials aside
from water. As all current iterations of the high-throughput irradiation apparatus have been
constructed with Lucite, considerable effort from our group has been placed to determine the
physical parameters of Lucite to be used within the Monte Carlo simulations. The effects of
density, ionization potential, tracking step size, target volume size, selected physics lists, etc.
have been investigated in part due to the need to understand these metrics for this work.
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In addition to uncertainty in biologic assays, using LET to quantitatively report the
RBE of charged particles is of limited value. When the physical quantity LET was first
introduced by physicists, it was intended to serve as a bridge to connect physics and biology.
LET, in some conditions, is convenient to explain radiobiologic observations. However,
when the LET spectrum is broad, such as at the Bragg peak or beyond, the usage of an
averaged quantity such as LETd cannot reflect the total effect of cell kill from all protons in
the spectrum and may introduce inaccuracy in reporting and quantifying RBE. Previous
studies from our group have shown that two very different LET spectra can result in the same
LETd but cause distinguishable cell survivals (125).
Despite these limitations, LET continues to be applied in particle radiobiology due to
its conceptual simplicity and convenience. Although using LET as a qualitative indicator of
biological effect can be convenient, one must be cautious when applying LET to quantify
RBE because doing so may result in misleading conclusions (3). In the ICRU Report No. 78
the committee stated that LET has utility in understanding the variation of RBE, but that LET
does not predict biological response with high accuracy for different cell or tissue systems
(10). In addition, the ICRU Report No. 86 warns that the use of macroscopic physical
quantities such as dose and LETd may obscure the finer details of the interactions between
ionizing particles and the biological system such as a cells or DNA (126). To overcome the
limitations of using LET, microdosimetry was introduced (127, 128). Our group is working
towards using microdosimetry to measure the stochastic analogs of dose and LET, specific
energy and lineal energy, to describe the detailed energy deposition spectrum at a small site
(micrometer scale) in order to better describe the consequent biologic effects.
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All results presented here are derived from in vitro or modified ex vivo systems. The
lack of in vivo biological response data is the main shortcoming of this work. While the
correlation between the clonogenic assay and tumor control probability is well established,
the setup to perform LET-based in vivo experiments in small animals is technically
challenging requiring high-precision custom holders (9, 50-53). This line of work is being
pursued and ongoing at the MD Anderson Proton Therapy Center.
An additional shortcoming of the presented work is the limited number of cell lines
and RBMTs used. Having developed the HT particle therapy irradiation methodology and
gained experience with its application including establishing the required infrastructure will
enable for immediate additional experiments. Future studies will focus on expanding the
repertoire of characterized cell lines. This is an especially significant task as there is data
suggesting proton RBE is dependent on a cell’s mutational profile. In particular, Liu et al.
found increased proton radiation sensitivity to be related to mutations in the Fanconi anemia
pathway. Their results are indicative of diverging DNA damage induction between photons
and clinically used protons (111). The identification of genetic markers correlated to
increased radiosensitivity to radiations containing higher LETs than photons could be used to
improve therapeutic outcomes by patient treatment stratification. The costs associated with
RBMT organoid model were prohibitive in the expansion of the studies which is why only 3
LETs are presented in this work. With additional funding, the entire range of LETs present
within a given ion beam will be sampled.
Overall, the HT measurements of proton beams indicate expected increases in RBE
with increasing LET. This phenomenon is especially pertinent at and beyond the Bragg peak
of the proton beam (Figure 103). Within the current clinical context, these findings indicate a
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non-static RBE which increases with depth and reaches a peak at the farthest distal regions of
an SOBP (Figure 104). Based on these findings, it will now be possible for the increased
biological effectiveness to be accounted for in treatment planning (Figure 105). To achieve a
biologically optimized IMPT treatment, the high LET regions of the beam would be
preferentially shifted within the tumor volume. One method this effect could be achieved is
with a form of proton-arc therapy; however, for the time, such a treatment would be difficult
to deliver due to the current size and subsequent rotation speed of gantries. Our results imply
that the evaluation of biologic effect must ensure comprehensive characterization and suggest
that additional studies using high-precision methods are required to further advance the
development of models of biologic effect for biologically optimized treatment planning.
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Figure 103. Application of measured RBEs to pristine proton beam. The data measured from
the HT clonogenic experiments can be applied to the physical dose (green) deposited to
weight the dose by the expected biological effects produced from a scanned proton beam in
an LET dependent manner using a biological response model such as the McNamara model
(red)(84). The expected RBE increase with LET serves to increase the differential biological
effects expected for a proton beam compared to a static RBE vs LET response (blue).
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Figure 104. RBEs applied to a traditional SOBP. In the context of the SOBPs currently used
in clinical practice, the application of the modeled RBE results yield an expected increase in
the biologically-weighted dose with increasing depth (red). This biological effect would be
most prominent in at the end and within the distal fall off of the SOBP.
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Figure 105. Achieving a uniform SOBP response. Within the present results, to achieve a
uniformly effective biological response with protons (red) requires the physical dose (black)
be lowered with depth in the SOBP. This dose deposition profile contains features analogous
to those in clinically used carbon ion plans.
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Conclusion
We have developed a methodology to perform high-throughput irradiations with
therapeutic particle beams. Using this framework, we have found the RBE to rapidly rise for
LETs present in the distal portions of protons beams in several in vitro biological response
models including adherent lung cancer cell lines, glioblastoma stem cell spheroidal cultures,
and normal rat brain microtissue organoids. Taken together, our results indicate that the
biological damage caused by proton radiation systematically increases with the LET of the
proton exposure for both cancerous and normal tissues. This finding suggests a non-static
proton RBE should be taken into consideration when performing treatment planning,
especially when using scanning beams. These results are applicable to traditional SOBPs in
areas that are subject to the lateral and distal portion of a beam where the resulting dose
deposition is from a single initial beam energy. In general practice these portions of the beam
are place beyond the tumor volume, within the normal tissue. Overall, the proton results
suggest that therapeutic gains may be achieved for proton therapy if the higher LET regions
of the beam are selectively placed within the tumor volume by reducing the biologically
effective dose received by the normal tissue while increasing the biologically effective dose
received by the tumor. The selective placement of higher LETs regions of the beams is
possible with the increasing use of IMPT.
While protons certainly offer improved dose distributions compared with current
photon-based therapies, with the potential to reduce normal tissue toxicities and late effects,
the region of the beam exhibiting significantly increased biologic activity, at and beyond the
Bragg peak, is a relatively small region of the total beam when compared to heavier ions.
This fact coupled with tissue repair repopulation effects and variations in patient setup over
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the course of a protracted fractionated treatment has conceivably played a significant role in
why the use of a static proton RBE value of 1.1 has been clinically effective with acceptable
rates of radiation induced side effects. However, a recent study by Peeler et al. detected the
first clinically derived evidence of dose and LET-dependent variable proton RBE in pediatric
ependymoma patients using MRI imaging changes (129). The results presented within this
work as well as found in the literature indicate that increased biological effects would be
observed in cases where the most biologically active portion of the beam is consistently
delivered. Within the current clinical environment of utilizing SOBPs, as patient setup
uncertainties are reduced or if special procedures involving hypofractionation are utilized,
additional toxicities would be expected in regions distal to the tumor volume. Utilizing
biologically-weighted IMPT will enable the delivery of protons to achieve optimal outcomes.
Looking towards the future of particle therapy, ions heavier than protons exhibit
increased differential and absolute biological effects over the entire beam range. Of major
importance are recent studies demonstrating unique biological consequences following heavy
ion therapy, in particular reduced metastatic potential and host-immune activation against the
tumor (6, 7, 35-38). Additional study is still required to appropriately cover the range of
potential biological outcomes for the numerous subtypes of cancer. Additionally, this data is
required to benchmark the results of comprehensive biophysical models needed for treatment
planning to the unique conditions present within the therapeutic region of the beam as well as
the fragmentation tail of heavier ion beams. It is the author’s hope that the results presented
or the application of the general methodology developed to produce high-throughput
irradiation data will be utilized in part to aid in this pursuit. In conclusion, the current results
presented, as well as global ongoing studies coupled with cost reducing technological
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developments present a future full of potential for the application of charged particle
radiation in the eradication of cancer.
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